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Microglia are the resident immune cells of the brain and have been implicated in mechanisms 
essential for cognitive functions. Down syndrome (DS), the most frequent cause of genetic 
intellectual disability, is caused by the presence of a supernumerary chromosome 21, which 
contains genes essential for the function of the immune system. Here, we investigated the 
presence of microglial alterations and their implication for cognitive impairment in the Dp(16) 
mouse model of DS. In the hippocampus of Dp(16) mice and individuals with DS, we found 
microglial morphology indicative of an activated state. Accordingly, we found increased levels of 
pro-inflammatory cytokines and a phagocytosis marker in Dp(16) mice. In addition, Dp(16) mice 
showed decreased dendritic spine density and cognitive deficits. Remarkably, depletion of 
defective microglia by PLX3397 treatment or rescue of the microglia activated state by the 
commonly used anti-inflammatory drug acetaminophen fully rescued dendritic-spine density and 
cognitive deficits in Dp(16) mice.  
Our data suggest an involvement of microglia in the cognitive impairment of DS animals and 










Chapter I: Down Syndrome  
Down syndrome (DS) is the main genetic cause of intellectual disability worldwide with a 
frequency of around 1 in 1000 live births (Khoshnood et al., 2011). It is caused by a supernumerary 
copy) or by a triplication of part of the human chromosome 21 (HSA21), usually due to meiotic 
non-disjunction during oogenesis (Dierssen, 2012; Hickey et al., 2012). Due to the fact that a long 
stretch of chromatin (∼48 Mb) containing around 235 protein-coding genes is triplicated, this 
condition is very complex and characterized by a series of different symptoms (Colacurcio et al., 
2018; Dierssen, 2012). Virtually all people with DS present some degree of cognitive impairment 
together with a wide range of other anomalies such as craniofacial deformations, congenital heart 
anomalies, thyroid diseases and immunological disorders (Dierssen, 2012; Hickey et al., 2012; Li et 
al., 2007; Sullivan et al., 2017). In addition, most individuals with DS by the age of 40 will develop 
Alzheimer’s disease (AD; (Hickey et al., 2012). Although there is no cure for this condition, life 
quality of individuals with DS can be greatly improved with proper health care and education. 
Indeed, in developed countries the life expectancy of these individuals is around 55 years (Roizen 
and Patterson, 2003). 
1.1 Cognitive impairments and pathophysiological changes 
Cognitive impairments are the most common and also one of the most debilitating symptoms of 
DS (Parrini et al., 2017; Roizen and Patterson, 2003). Individuals with DS show deficits in many 
different cognitive domains with severe impairment in language and vocabulary development 
(Dierssen, 2012). Moreover, short-term memory as a whole is highly impaired as well as the 
acquisition and storage of explicit memory. Of note is the fact that DS individuals have an almost 
intact visuospatial memory (Dierssen, 2012). A wide range of pathophysiological changes in brains 
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from individuals with DS have been observed with an overall reduction of brain volume that 
comprises many of the brain areas (Fig. 1) together with extensive evidence showing that brain 
regions are wired atypically in the DS compared to non-DS individuals (Dierssen, 2012). For 
example, the corpus callosum is smaller in DS suggest an overall decreased of connectivity 
between brain hemispheres (Teipel et al., 2003). In addition, the frontal lobe have been 
extensively shown to have decreased connectivity with other brain areas considered important for 
learning and memory such as the hippocampus and the basal ganglia (Dierssen, 2012; Pujol et al., 
2015). Interestingly, imbalances in excitation/inhibition (especially in the hippocampus), are 
present in DS and could be an interesting target for recovering cognition (Belichenko et al., 2009; 
Deidda et al., 2015; Parrini et al., 2017).  
 
Figure 1. Brain changes in individuals with Down syndrome (Adopted from Dierssen, 2012). 
 
At a cellular level, neurons from individuals with DS as well as from DS animal models (i.e., Tc1, 
Ts1Rh1, Ts65Dn and Ts1Cje mice), show alterations in number and shape of dendritic spines 
(Belichenko et al., 2009; Haas et al., 2013; Herault et al., 2017; Torres et al., 2018). 
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 Dendritic spines are structures on dendrites that protrude outwards and function as 
compartments for excitatory synaptic elements in excitatory synapses (Nakahata and Yasuda, 
2018). Defective dendritic spine structure and number, together with their function are a very 
important feature of a wide range of neurodevelopmental disorders, including DS, and probably 
underlie alterations in neuronal and synaptic plasticity, ultimately having an impact on cognition 
(Torres et al., 2018). Dendritic spines are very dynamic structures that can assume a wide range of 
morphological states (Fig. 2) going from filiform (immature spines) to mushroom spines (mature, 
immobile spines) passing through more mobile shapes such as stubby and thin (mature, immobile 
spines; (Risher et al., 2014).  
 
Figure 2. Dendritic spine morphologies. Dendritic spines can assume a wide range of 
morphological states (Adopted and adapted from Risher et al. 2014). 
 
Spine dynamics are necessary for learning and memory (Bosch et al., 2014; Salter and Stevens, 
2017) and its dynamicity is due to the actin cytoskeleton and a wide range of protein that can 
interact with actin itself stabilizing or destabilizing its structure (i.e., drebrin and profilin; 






Figure 3. Dendritic spine structure. Dendritic spines are 
very dynamic structures. Their dynamicity is due to 
actin and its interactors, such as drebrin (DBN; Adopted 




Drebrin (DBN) is one of the most important actin-stabilizing proteins in dendritic spines where it is 
highly expressed and exerts a pivotal role in maintenance and maturation (Koganezawa et al., 
2017). Interestingly, drebrin levels are drastically decreased in individuals with DS (Shim and 
Lubec, 2002; Weitzdoerfer et al., 2001).  
1.2 Immune system dysregulation  
In addition to cognitive disability, individuals with DS often suffer from intrinsic immunological 
dysfunctions such as an increased risk of infections, hematological and autoimmune disorders 
resulting in higher hospitalization and mortality rates (Guaraldi et al., 2017; Schoch et al., 2017). 
Accordingly, individuals with DS present dysregulation in a wide range of immune system-related 
cells and factors. Indeed, defects are present in both the innate (the first component of the 
immune system to activate upon pathogen presentation) and adaptive immune system (the 
component of the immune system that is activated after the activation of the innate immune 
system relies on tackling specific antigens; (Joseph et al., 2018). The adaptive immunity of 
individuals with DS show alterations typically seen in the elderly (i.e., lack of diversity among naive 
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circulating T and B cells and a dysregulated development of fully differentiated B and T cells; (Ram 
and Chinen, 2011; Schoch et al., 2017). In addition, immune response following vaccination is 
decreased probably due to a smaller number of circulating memory B cells (Schoch et al., 2017; 
Valentini et al., 2015). Circulating antibodies in individuals with DS are also strongly altered, with 
significant alteration of IgM, IgG and IgA (Eijsvoogel et al., 2017; Ram and Chinen, 2011). 
Interestingly, the acuteness of the changes in T and B cells have been correlated with 
prospectively identified infection-related hospitalizations in children with DS (Martinez et al., 
2016). In addition, higher levels of circulating pro-inflammatory cytokines such as Tumor Necrosis 
Factor α (TNF-α), Interleukin-1 β (IL-1β), IL-6, Monocyte Chemoattractant Protein 1 (MCP-1), IL-22, 
Interferon γ (IFN-γ) as well as higher activation of the complement cascade are present in persons 
with DS (Sullivan et al., 2017; Zhang et al., 2017). Moreover, the interferon-response cascade is 
constantly activated in DS with a consequent decrease in protein synthesis and further release of 
pro-inflammatory molecules (Sullivan et al., 2017; Sullivan et al., 2016), or, as defined by Sullivan 
et al. 2016: “(…) the cells of people with Down syndrome are constantly fighting a viral infection 
that does not exist.” 
Although the brain is tightly sealed by the blood brain barrier (BBB), it partially touched by the 
immune system. The (only) representative of the immune system in the Central Nervous System 
(CNS) are the microglia (Kaur et al., 2017). Interestingly, together with higher level of 
neuroinflammation and increased pro-inflammatory cytokines levels persons with DS show 
microglial and astroglial activation (Rueda et al., 2018; Streit et al., 2014; Wilcock and Griffin, 
2013; Xue and Streit, 2011). Finally, neurons from individuals with DS and the Ts65Dn mouse 
model overexpress the COX2 enzyme, one of the most prominent markers of inflammation (Mulet 
et al., 2017). This increase in neuroinflammation in DS may exacerbate the cognitive deficits in 
which pro-inflammatory molecules may affect neuronal proliferation, decrease neurogenesis, and 
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impair neuronal maturation and wiring (Rosi et al., 2012; Rueda et al., 2018; Salter and Stevens, 
2017). Moreover, increased microglia-mediated synaptic synaptic elimination may underlie some 
of the defects observed (Salter and Stevens, 2017). Finally, neuroinflammation is one of the main 
contributors for the progression of AD. Interestingly, the Amyloid-Precursor Protein (APP) and the 
consequent Aβ aggregate promote neuroinflammation themselves. The higher level of basal 
neuroinflammation together with the triplication of the App gene could therefore explain the high 
susceptibility of DS persons to developing AD and dementia (Hartley et al., 2015; Rueda et al., 
2018). 
1.3 Animal models of Down Syndrome 
Mice have around 158 genes that are orthologous to genes triplicated in people with DS. These 
orthologous genes lay on Murine Chromosome 10, 16, and 17, with most of them on Chromosome 
16 (MMU16; (Herault et al., 2017). This lead researchers to develop a wide range of mice strains 
containing total or partial triplication of the MMU16 (Fig. 4). The first viable DS murine model ever 
developed was the Ts65Dn in 1990 (Davisson et al., 1990). Since then, the scientific community 
made huge efforts forward on the development of new and cleaner models. However, the Ts65Dn 






Figure 4. Diagram showing the chromosomic structure of the most commonly used DS mouse 
models with triplications on genes located in mouse Chromosome 16. The human chromosome 
21 (HSA21) and the mouse chromosomes that contain genes orthologue to the HSA21 (Chr. 16, 17 
and 10) are depicted. The Tc1 mouse is the only one that contains the whole HSA21 (black bars 
represent deletions included in the Tc1 chromosome), the other models bear a triplication or a 
partial triplication of the MMU16 (Adopted and adapted from Hartley et al. 2016). 
 
The only model developed that contains the whole HSA21 is the Tc1 mouse (O'Doherty et al., 
2005). In the Tc1 mouse however, during cell proliferation the HSA21 is stochastically lost 
generating at the end a mosaic animal: this huge drawback hindered a wider use of this model 
(Herault et al., 2017). With the development of a new genomic engineering technique, the Cre/Lox 
system, a wide range of partial MMU16-triplication bearing strains were developed (i.e. 
Dp(16)yey, Ts1Yu; (Herault et al., 2017); Fig. 4). The Dp(16)yey model of DS (hereafter referred to 
as Dp(16)), bears on one chromosome 16 a duplication orthologous to the region q11-q22.3 of 
HSA21 (Li et al., 2007). Therefore, Dp(16) mice have three copies of 113 genes orthologous to 










Dp(16) mice recapitulate many of the characteristics of human syndrome such as craniofacial 
defects, gastrointestinal dysfunctions, and, most importantly, cognitive deficits (Goodliffe et al., 
2016; Jiang et al., 2015; Li et al., 2007). Indeed, Dp(16) mice have defective behavior in many 
cognitive behaviors such as T-Maze test, Fear Conditioning and Morris Water Maze (Goodliffe et 
al., 2016; Jiang et al., 2015; Yu et al., 2010). Similar deficits have also been observed in the Ts65Dn 
mouse (Deidda et al., 2015; Parrini et al., 2017; Raveau et al., 2018). Interestingly, hippocampal 
Long Term Potentiation (LTP) in Dp(16) as well as in Ts65Dn are defective (Dierssen, 2012; Jiang et 
al., 2015). Moreover, an increased number of interneurons in the hippocampus of Dp(16) mice 
was observed together with significant decrease in the ability of bursting and producing complex 
spikes of CA1 pyramidal cells. This in turn may alter the ability of acquiring and consolidating 
spatial memories (Raveau et al., 2018).  
Evidence from the study of postmortem fetal brains of individuals with DS and from animal 
models, namely Ts65Dn, Ts1Cje, and Ts16, have indicated a wide range of prenatal abnormalities 
such as reduced proliferation and neurogenesis, delayed neocortical expansion, and microcephaly 
(Contestabile et al., 2007; Goodliffe et al., 2016; Guidi et al., 2008). However, it has been 
unexpectedly shown that the Dp(16) mice present none of these neuron-related pre-natal defects 
(Goodliffe et al., 2016). On the other hand, at the second post-natal week Dp(16) animals 
presented delayed developmental milestones and deficits in motor and cognitive behavior, 
suggesting that the post-natal development is sufficient to generate most of the deficits that 
recapitulate the human condition (Goodliffe et al., 2016).  
Nevertheless, to date, there is no extensive analysis of the immune system dysregulation in animal 
models of DS. However, in Ts65Dn it is possible to put together evidence showing that also in the 
animal model of DS the immunological deficits are recapitulated (Hartley et al., 2015). An early 
report reported that the treatment of pregnant Ts65Dn dams with an antibody against IFNγ was 
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able to rescue fetal growth (Maroun, 1995), which is in line with the more recent notion that in DS 
the IFNγ is abnormally activated (Sullivan et al., 2017; Sullivan et al., 2016). Interestingly, reports 
have shown that the Ts65Dn animals have smaller thymus, alterations in T and B cells, 
hematopoietic stem cells and lymphoid progenitor cell defects (Lorenzo et al., 2011; Lorenzo et al., 
2013). Moreover, evidence point toward increased levels of neuroinflammation with increased 
microglia activation and overexpression of COX2 enzyme (Hunter et al., 2004; Mulet et al., 2017; 
Rueda et al., 2018). Remarkably, a recent report showed that blocking the action of the pro-
inflammatory IL-17 was able to rescue hippocampal hypocellularity and neurogenesis together 
with an amelioration of cognitive abilities, APP expression and overall neuroinflammation, strongly 
suggesting that inflammation is indeed present in this mouse model and that it plays a very 
important role in exacerbating cognitive deficits (Rueda et al., 2018). To date there are no detailed 
reports on inflammation in Dp(16) mice. It was however shown that IFNα/β and IFNγ receptors are 











Chapter II: Microglia 
The brain is isolated from the periphery by the BBB. This implies that macrophages cannot have 
access to the nervous tissue in a healthy state. However, there are resident immunological cells in 
the CNS, the microglia (Ginhoux et al., 2013), the brain macrophages. Microglia are cells mainly 
derived from a mesodermic structure called the yolk sack and very early in development (around 
E9 in mice and 4.5 gestational weeks in humans) they invade the neural tube (Ginhoux et al., 2013; 
Tay et al., 2017b). A second wave of invasion of macrophages (that later differentiate into 
microglia) deriving from the fetal liver happens at E13 in mice and the 12-13 gestational week in 
humans (Ginhoux et al., 2013; Tay et al., 2017b). Upon the closure of the neural tube, the 
microglial cells differentiate into a stable microglial population (Tay et al., 2017b). Although it is 
thought that all the microglia derives from c-kit+ cells from the yolk sack and fetal liver very early 
in development, the possibility that a second wave of microglial cells arrives in the CNS from the 
bone marrow postnatally still remains controversial (Fig. 5; (Tay et al., 2017b). In adults under 
physiological conditions, microglial cells show a ramified morphology, and they constantly surveil 
the brain parenchyma (Nimmerjahn et al., 2005; Tremblay et al., 2011). Then, in the case of injury 
and in the presence of pro-inflammatory molecules, microglial cells shift morphology to a mobile, 
more amoeboid (larger cell body and fewer ramifications) form (Fig. 6; (Cunningham et al., 2013). 
Together with their morphological change, microglia upregulate activation and phagocytosis 
markers (e.g., MHCII, Iba1 and LAMP1, respectively) during inflammation (Arcuri et al., 2017; 
Hanisch and Kettenmann, 2007; Shobin et al., 2017; Sipe et al., 2016). Moreover, in case of injury 
or systemic inflammation, the BBB allows the passage of macrophages from the periphery 





Figure 5. Microglia have a mesodermal origin. Microglia are mainly derived from c-kit+ cells from 
the yolk sack and later from the fetal liver. Before the closure of the neural tube the microglia 
population is isolated from the periphery reaching a steady-state. In case of inflammation or 
injury, macrophages derived from the bone marrow can cross the BBB and differentiate into 
microglia-like cells (Adopted from Ginhoux et al. 2013)  
 
Figure 6. Microglia can drastically change morphology during development or inflammation. 
Diagram showing confocal images of different morphological states of microglia. From left to right 
the morphology changes from amoeboid to ramified. The same direction of the morphology 
change is observed during development or after inflammation (Adopted and adapted from 
Cunningham et al. 2013). 
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Interestingly, microglia also play an important role in brain development and plasticity (Arcuri et 
al., 2017; Tremblay et al., 2011). Microglia can regulate neuronal death and can phagocyte 
neuronal progenitors (Kaur et al., 2017). In addition, they play an essential role in phagocyting 
apoptotic cells in the developing brain. Indeed, apoptotic cells release factors such as the 
Macrophage Inflammatory Protein (MIP) that in turn activates and attracts microglia to the 
apoptosis site (Arno et al., 2014). Moreover, microglia are able to control the number of 
progenitor cells in the developing cortex and are sensitive to factors released by neural progenitor 
cells (Mosher et al., 2012; Tay et al., 2017b). Interestingly, microglia regulate neurogenesis also in 
the adult brain (in the Sub Ventricular Zone (SVZ) and sub granular zone in the hippocampus; 
(Sierra et al., 2010). In agreement with this notion, removal of microglia from the SVZ hampers the 
survival and the migration of neuroblasts destined to the olfactory bulb (Xavier et al., 2015). 
Moreover, microglia are very important for the correct wiring of neuronal circuits during 
development, giving support to growing axons and phagocyting debris (Tay et al., 2017b). 
Postnatally, microglia play a pivotal role in shaping circuits through synaptic elimination. Microglial 
activity is necessary for the correct formation of activity-driven synaptic maturation, critical period 
plasticity and physiological synaptic elimination during adolescence (Miyamoto et al., 2016; 
Paolicelli et al., 2011; Sipe et al., 2016; Squarzoni et al., 2015; Stevens et al., 2007; Tay et al., 
2017b). 
2.1 Microglia and cognition 
Peripheral inflammation and inflammation of the nervous system have been extensively linked to 
decreased cognition in the young and physiologically aging brain, pointing toward a probable 
immunological regulation of learning and memory (Benson et al., 2017; Bharani et al., 2017; 
Marsland et al., 2015; Riazi et al., 2015; Salter and Stevens, 2017; Shobin et al., 2017; Todd, 2017). 
Interestingly, neurons and microglia are in constant communication and the contact between 
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microglial cells and neurons can result in changes of neuronal activity. In addition, pro-
inflammatory cytokines released by microglia such as IL-1β, IL-6 and complement activation 
reduce LTP and reduce overall synaptic plasticity in the brain (Tchessalova et al., 2018; Wu et al., 
2015). Moreover, activation of microglial activity with lipopolysaccharide (LPS) induces a decrease 
in LTP and an increase in Long-Term Depression (LTD) in hippocampal rat slices, strongly 
suggesting that microglia can interfere with mechanisms underlying cognition (Pascual et al., 2012; 
Wu et al., 2015). Remarkably, inhibition of microglial activity with minocycline (an anti-
inflammatory tetracycline) is able to prevent inflammation-related cognitive impairments in rats 
(Wadhwa et al., 2017). Interestingly, deficiency in one of the main signaling pathways in microglial 
cells, the CX3CR1, deletion of microglia-produced Brain Derived Neurotrophic Factor (BDNF) or 
microglial depletion lead to cognitive impairment in mice when assessing fear conditioning and 
motor behavior (Parkhurst et al., 2013; Rogers et al., 2011; Tay et al., 2017b). In addition, CX3CR1
KO 











Chapter III: Microglia in Neurodevelopment Disorders 
Neurodevelopmental disorders are a group of diseases which onset is early in life and often are 
characterized by deficits in sociability, cognitive problems, and obsessive/compulsive behavior and 
sometimes motor abnormalities (Arcuri et al., 2017). The pathophysiology of these disorders are 
very heterogeneous and therefore hard to study. However, deficits in synaptic maturation 
together with weak functional connectivity or an excess of weak excitatory synapses seem to play 
a very important role (Arcuri et al., 2017). Because microglia play an essential role in the synaptic 
pruning and shaping of circuits during development it has been proposed that the alteration of 
these cells may participate in the pathogenesis of these disorders (Salter and Stevens, 2017). 
Indeed, in the last 10 years there have been a significant increase in the number of findings 
showing that neurodevelopmental disorders such as autism, Down Syndrome, Rett Syndrome, 
Schizophrenia and Tourette Syndrome are accompanied by microglial disease. On the other hand, 
whether the microglial deficits are causing the disorder or if it is the diseased brain environment 
that is causing microglial dysfunction is still a matter of discussion (Salter and Stevens, 2017; Streit 
et al., 2014; Tay et al., 2017a). Interestingly, a number of post-mortem studies have shown 
alterations in microglia count and morphology together with a shift in the transcriptomics towards 
a more inflammatory state in the brains from individuals with autism (Gupta et al., 2014; Morgan 
et al., 2010; Suzuki et al., 2013; Tetreault et al., 2012; Vargas et al., 2005). Moreover, animal 
studies have shown that CX3CR1
KO animals (which have decreased number of microglia), show 
insufficient pruning during development and display repetitive behavior and deficits in sociability, 
two behaviors that are believed to be related to autism (Salter and Stevens, 2017). Accordingly, 
treatment with a wide variety of anti-inflammatory molecules such as luteolin, minocycline and 
suramin attenuate the autistic-like behavior, especially in the social area (Kim et al., 2018). 
Interestingly, it has been proposed that microglia play an important role in shaping the autistic 
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brain. Indeed, the elevation of the levels of pro-inflammatory cytokines (i.e. IL-6, IL-1β, TNF-α) 
obtained by the treatment of pregnant dams with LPS or polinosinic:poly-cystidylic acid (poly I:C), 
strongly alter the brain wiring and induces the appearance of autistic-like behavior in the offspring 
(Kim et al., 2018). Likewise, schizophrenia and Tourette Syndrome have been also linked to 
increased microglial activation (Arcuri et al., 2017; Chung et al., 2015). Remarkably, individuals 
that suffer of schizophrenia show increased microglial activation in the whole gray matter of the 
brain (van Berckel et al., 2008), as shown by Positron Emission Tomography (PET) imaging. Indeed, 
the drug minocycline (which inhibits microglia activation) is currently under investigation as 
alternative antipsychotic (Inta et al., 2017). Interestingly, microglia play a role also in Rett 
syndrome (RTT). RTT is caused by the inactivation of the X-linked MeCp2 protein that is pivotal for 
the epigenetic regulation of the activation many genes (Xu and Pozzo-Miller, 2017). For long it was 
thought that MeCp2 was expressed only in the neurons but recent evidence show that microglia 
also express high levels of this protein (Maezawa and Jin, 2010). Accordingly, RTT microglia release 
toxic factors for neurons and potentially play a pivotal role in the synaptic and dendritic 
dysfunctions characteristics of this condition (Maezawa and Jin, 2010). Moreover, MeCp2-/- 
microglia show deficiency in phagocytosis and inability of debris clearance in the brain which could 
in turn contribute to neuronal toxicity (Arcuri et al., 2017). Interestingly, microgliosis is absent in 
RTT brains and the levels of pro-inflammatory cytokines seem to be normal, suggesting that in the 
case of RTT syndrome microglia acts through an intrinsic mechanism that is not related to chronic 
inflammation (Arcuri et al., 2017).  
On what concerns DS the evidence is very fragmented. Early reports have shown that brains from 
individuals with DS show elevated expression of IL-1 in the microglia and astrocytes. The brains 
used for these analysis were however from DS persons that presented signs of AD (Griffin et al., 
1989). In addition, a more recent study conducted on brains from aged DS individuals showed that 
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a large proportion of the microglia is in a senescent state, similar to AD patients (Xue and Streit, 
2011). On the other hand, in another report, fetuses with DS showed increased microglial number, 
suggesting a role of these cells during development in DS (Wierzba-Bobrowicz et al., 1999). 
Accordingly, DS fetuses have increased number of infiltrating macrophages (CD68+ cells) in the 
gray matter, CA1 and the subiculum regions of the hippocampus (Kanaumi et al., 2013). 
Interestingly, early in vitro studies have shown that microglial cultures from Ts16 mice show higher 
production of superoxide when exposed to Ts16 astrocyte-conditioned media, suggesting that 
trisomic microglia are hyperactive when insulted (Colton et al., 1990). In addition, the same group 
showed that trisomic microglia produce increased levels of IL1-β (Colton et al., 1991). More 
recently, work done on Ts65Dn animals have shown increased number and higher activation levels 
of microglia, deficit that could be rescued with treatment with minocycline together with the 
rescue of working memory in these animals (Hunter et al., 2004). Two remarkable studies 
conducted recently strongly support the idea that also in DS there is microglial pathology. It has 
been shown that microglia from DS patients and Ts65Dn mice show elevated levels of the COX2 
enzyme. This enzyme is upregulated during inflammation and often is used as a marker of 
microglial activation (Mulet et al., 2017). In addition, treatment of 11 months-old Ts65Dn animals 
with anti-IL-17, a potent pro-inflammatory cytokine, was able to rescue the hyper activation of 
microglia together with cognitive abilities. These findings strongly support the idea that hyper 
active microglia might play a role in DS (Rueda et al., 2018). The active microglia in DS could 
potentially produce aberrant synaptic elimination of dendritic spines. Indeed, dendritic spine 
deficits have been extensively described in persons with DS and in DS murine models, and they 
have been suggested to play a role in DS cognitive disability (Belichenko et al., 2004; Dierssen, 
2012; Dierssen et al., 2003; Haas et al., 2013; Takashima et al., 1994). An increased immunological 
activity with a subsequent increase in microglial activation and spine elimination could therefore 
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play a role in the cognitive deficits in DS (Kleschevnikov et al., 2004; Parrini et al., 2017). Taken 
together, a very clear picture starts to appear: the activation of the immune systems seems to be a 
common factor in neurodevelopmental disorders. However, the phenotype produced might be 
different than the simple acute inflammation. Indeed, the long-term increase of pro-inflammatory 
cytokines in the brain results in a notably different network of pro-inflammatory molecules and as 
a result in a different brain state when compared to an acute inflammatory situation (Tchessalova 
















Chapter IV: Acetaminophen 
Acetaminophen (APAP, Fig. 7) is an unconventional non-steroidal anti-inflammatory drug (NSAID) 
that likewise other traditional NSAIDs decreases the synthesis of prostaglandins (PGE) and has 
antipyretic and analgesic effects. Although APAP is considered to not have anti-inflammatory 
effect (Jozwiak-Bebenista and Nowak, 2014), it was shown that APAP is very active in the central 
nervous system on blocking the COX enzymes (Flower and Vane, 1972; Jozwiak-Bebenista and 
Nowak, 2014). Moreover, APAP has been shown to strongly act on microglial cells significantly 
diminishing the PGE production by microglial cells at low concentrations (Ajmone-Cat et al., 2010; 
Greco et al., 2003). Indeed, APAP could completely block the production of prostaglandin E2 (PGE2) 
even in microglia stimulated with LPS without having an effect on the COX2 protein synthesis 
(Fiebich et al., 2000; Greco et al., 2003; Saliba et al., 2018). 
 
 Figure 7. APAP Structure. Chemical structure of acetaminophen. The 
IUPAC chemical name is N-actetyl-para-aminophenol. (Adopted and 
adapted from Jozwiak-Bebenista and Nowak, 2014) 
 
The mechanism of action of this drug is still matter of discussion although it is believed to have a 
blocking action on mainly the COX2 isoform likewise traditional NSAIDs with a great dependence 
on the reduction/oxidation state (redox) of the surrounding environment (Jozwiak-Bebenista and 
Nowak, 2014). Moreover, although acetaminophen is well known for being a potential hepatotoxic 
drug, it is extremely safe even at relatively high doses (up to 4 grams daily for adults) and it lacks 
the gastric side effects typical of the classical NSAIDs (Ajmone-Cat et al., 2010). However, on what 
concerns the effects on the brain, recent studies on animals and humans has begun to raise some 
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concerns about the safety of APAP during gestation and early postnatal stages because it can 
influence physiological brain development (Blecharz-Klin et al., 2015; Blecharz-Klin et al., 2018; 
Good, 2018; Philippot et al., 2017; Schultz and Gould, 2016; Viberg et al., 2014). Indeed, the 
administration of APAP to rats caused a significant decrease in spatial memory, social behavior 
and exploratory behavior (Blecharz-Klin et al., 2018; Ishida et al., 2007). Remarkably, recently it 
was discovered that a single administration of APAP (100mg/kg) caused object-recognition deficits 
and hyper-phosphorylation of extracellular signal-regulated kinase (ERK) in the dorsal mouse 
hippocampus (Milewski and Orr, 2018). On the other hand, APAP has positive effects on complex 
behaviors when administered postnatally to non-Wild-Type (WT) animals. For instance, the 
administration of 100mg/kg of APAP to BTBR mouse (a strain that is characterized by autistic-like 
behaviors such as decreased sociability) rescued the social deficits in these animals (Gould et al., 
2012). Strikingly, a recent report showed that APAP treatment prevented the LPS-induced 
cognitive deficits in mice by means of Morris Water Maze and had a strong effect on decreasing 
the LPS-induced increase in pro-inflammatory molecules such as IL-1β, IL-6 and TNF-α. Notably, 
APAP acted mainly on microglia eliciting also a decrease in the LPS-induced microglial proliferation 
(Zhao et al., 2017). Remarkably, APAP can indeed change complex human behaviors such as social 
anxiety (Fung and Alden, 2017), empathy (Mischkowski et al., 2016) and social well-being (Chibnall 
et al., 2005). Interestingly, the only report that has studied the effects of APAP in cognition show 
that healthy volunteers treated once with 2g of APAP showed sharpened reflections and spatial 
memory (Pickering et al., 2016). This notable report supports the idea that APAP may have 
unexpected actions on complex behavior in humans and even on cognition. Altogether, these 
findings shed light on the role of inflammation and microglia in cognition and support the idea that 





Dp(16) microglia have larger cell bodies and fewer ramifications than WT microglia 
To start our investigation on the role of microglia in DS, we first counted the number and analyzed 
the morphology of microglial cells in hippocampal brain slices (stratum pyramidalis of the CA1, 
CA3 and DG regions) from young adult animals (postnatal day (P)22) of the Dp(16) mouse model of 
DS and WT littermates (Fig. 8a). Whereas we found no difference in the number of microglia 
between the two strains (Fig. 8b-c), the whole microglial population of Dp(16) mice presented 
enlarged cell bodies (Fig. 8d-e). In addition, Dp(16) microglia exhibited a drastic impairment of 
branching, with a strong reduction in the median length of branching distribution starting from the 
cell body, as quantified by Sholl analysis (Sipe et al., 2016); Fig. 8f-h). A subsequent skeleton 
analysis performed on the same cells further revealed an significant decrease in branch numbers, 
with no changes in average branch length (Fig. 8i-k). When we compared the trisomic and WT 
microglia in the somatosensory cortex, we found a cell-body enlargement in trisomic microglia 
similar to that observed in the hippocampus (Fig. 9a-d), but no differences in branch number and 
distribution between the two strains (Fig. 9e-i). However, we observed a significant increase in the 
average length of the branches developed by trisomic microglia (Fig. 9j), suggesting that the area 
surveilled by each cell is larger in Dp(16) than in WT somatosensory cortices. 
Altogether, these data show that microglia present a more amoeboid morphology in Dp(16) mice, 
suggesting a higher level of baseline activation than in WT littermates. 
Dp(16) mice show increased levels of inflammation in the hippocampus 
Activated microglia express high levels of MHCII and Iba1 (Arcuri et al., 2017; Hanisch and 
Kettenmann, 2007; Sipe et al., 2016) and secrete large amounts of pro-inflammatory cytokines 
(Ajmone-Cat et al., 2010; Kierdorf and Prinz, 2013). Thus, to quantify the level of activation of 
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microglia in the hippocampus of DS mice, we first analyzed the expression of MHCII (via 
immunohistochemistry) and of Iba1 (via western blot) in Dp(16) and WT littermates at P22. In the 
trisomic mice, we found no alterations in the MHCII levels (Figure 10), whereas we found 
increased Iba1 levels in comparison to WT mice (Fig. 11a). We then measured 40 cytokines using 
an antibody array. We found a significant increase in the levels of 15 cytokines (Fig. 11b-c, Fig. 12), 
suggesting that the basal level of microglial activation was increased in the hippocampus of Dp(16) 
mice. Since the phagocytic action of microglia is increased upon activation (Shobin et al., 2017) 
and this regulates neural activity and plasticity (Sipe et al., 2016; Wu et al., 2015), we next 
analyzed the overall level of phagocytosis via immunoblotting of the lysosomal marker LAMP1 in 
the hippocampus of Dp(16) and WT littermates. We found increased levels of LAMP1 in the Dp(16) 
hippocampi (Fig. 11d). To specifically analyze the levels of LAMP1 in microglial cells, we turned to 
immunohistochemistry. We found increased LAMP1 immunolabeling in trisomic microglia (Fig. 
11e-f), suggesting increased phagocytosis. 




Figure 8. Microglial morphology is altered in Dp(16) hippocampi. (a) Experimental protocol used 
for analyzing the morphology of microglia in the CA1, CA3 and DG areas of the hippocampus 
(highlighted by the dotted lines). (b) Representative confocal images of Iba1-stained hippocampal 
slices from P22 WT (blue) and Dp(16) (orange) animals. Scale bar: 10μm. (c) Quantification of Iba1+ 
cell density in the hippocampus in experiments as in b. Bars represent the average cell density of 
all analyzed animals ± SEM and circles represent the single data points for each animal (1 slice per 
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animal). (d) Quantification of the cell body area of microglial cells in experiments as in b. Bars 
represent the average of microglial cell body areas in all analyzed animals ± SEM and circles 
represent the single data points of the cell averages for each animal (38-73 cells/animal; 1 slice per 
animal). * p<0.05; Unpaired Two-tailed Student’s t-test, t=2.8, df=14. (e) Cumulative distribution 
of the microglial cell body area of all analyzed cells, calculated as the percentages of the cells 
inside each bin area. The two distributions are significantly different (Kolmogorov-Smirnov Test, 
p<0.001). Numbers in parenthesis: analyzed cells, and animals. (f) Binary images of the fields 
shown in b. Scale bar: 10μm. (g) Sholl analysis of microglial cells in images as in f. Data are 
expressed as average number of intersections at each distance from the cell bodies of all analyzed 
cells ± SEM. * p<0.05, ** p<0.01, *** p<0.001; Two-Way ANOVA, FStrain (33, 7650) = 317.5, p < 
0.001; Holm-Sidak post-hoc test. Numbers in parenthesis: analyzed cells, and animals (1 slice per 
animal). (h) Quantification of the median distance of the intersections from the cell body, as 
obtained from the Sholl analysis in g. Bars represent the average of the median distances in all 
analyzed animals ± SEM, and circles represent the single data points of the median distance 
averages for each animal (12-21 cells/animal; 1 slice per animal). * p<0.05; Unpaired Two-tailed 
Student’s t-test, t=4.98, df=11. (i) Representative skeleton images of binary images in f. Scale bar: 
10μm. (j) Quantification of the number of branches per microglial cell in images as in i. Bars 
represent the average of the number of branches per microglial cell ± SEM in all analyzed animals, 
and circles represent the single data points of the cell averages for each animal (12-21 
cells/animal; 1 slice per animal). * p<0.05; Unpaired Two-tailed Student’s t-test, t=4.03, df=11. (k) 
Quantification of the average length of branches per microglial cell in images as in i. Bars represent 
the average of branch length per microglial cell ± SEM in all analyzed animals, and circles represent 





Figure 9. Microglial morphology is altered in the somatosensory cortex of Dp(16) mice.  
(a) Experimental protocol used for analyzing the morphology of microglia in the somatosensory 
cortex (highlighted by the dotted lines). (b) Representative confocal images of Iba1-stained 
somatosensory cortices from P22 WT and Dp(16) animals. Scale bar: 20μm. (c) Quantification of 
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the cell body area of microglial cells in experiments as in b. Bars represent the average of 
microglial cell body areas in all analyzed animals ± SEM and circles represent single data points of 
the cell averages for each animal (72-126 cells/ animal; 1 slice per animal). *** p<0.001; Unpaired 
Two-tailed Student’s t-test t=6.3, df=13. (d) Cumulative distribution of the microglial cell body area 
of all analyzed cells, calculated as the percentages of the cells inside each bin area. The two 
distributions are significantly different (Kolmogorov-Smirnov Test, p<0.001). Numbers in 
parenthesis: analyzed cells, and animals. (e) Binary images of the fields shown in b. Scale bar: 
20μm. (f) Sholl analysis of microglial cells in images as in e. Data are expressed as average number 
of intersections at each distance from the cell bodies of all analyzed cells ± SEM. Numbers in 
parenthesis: analyzed cells, and animals (1 slice per animal). (g) Quantification of the median 
distance of the intersections from the cell body, as obtained from the Sholl analysis in f. Bars 
represent the average of the median distances in all analyzed animals ± SEM, and circles represent 
the single data points of the median distance averages for each animal (20-41 cells/animal; 1 slice 
per animal). (h) Representative skeleton images of binary images in e. Scale bar: 20μm. (i) 
Quantification of the number of branches per microglial cell in images as in h. Bars represent the 
average number of branches per microglial cell ± SEM in all analyzed animals, and circles represent 
the single data points of the cell averages for each animal (20-41 cells/animal; 1 slice per animal). 
(j) Quantification of the average length of branches per microglial cell in images as in h. Bars 
represent the average of branch length per microglial cell ± SEM in all analyzed animals, and circles 
represent the single data points of the cell averages for each animal (20-41 cells/animal; 1 slice per 
animal). ** p=0.0068; Mann-Whitney test, U=12. 
 
Figure 10. MHCII is not upregulated in Dp(16) animals. Representative confocal images of MHCII-
stained (red) hippocampal slice from P22 WT and Dp(16) animals showing no immunoreactivity. In 
the negative control, the primary anti-MHCII antibody was omitted. Animals treated with 1mg/kg 






Figure 11. Hippocampi show increased levels of Iba1 and LAMP1 immunoreactivity, and 
cytokines in Dp(16) mice. (a) Representative immunoblots on protein extracts from lysates of 
hippocampi obtained from P22 WT and Dp(16) mice (left). Quantification of Iba1 protein levels 
normalized to GADPH immunoreactivity (right). Bars represent the average percentage of Iba1 
levels in Dp(16) over WT hippocampi for all the analyzed animals ± SEM, and circles represent the 
single data points for each animal. ** p<0.01; Unpaired Two-tailed Student’s t-test, t=3.21, df=28. 
Data were averaged across 6 independent experiments. (b) Representative cytokines arrays 
performed on hippocampal lysates obtained from P22 WT and Dp(16) animals. The dashed circles 
show the cytokines significantly dysregulated between the two groups as quantified in d. (c) 
Quantification of all the cytokines significantly increased in Dp(16) vs WT hippocampi. Bars 
represent the average percentage of cytokine levels in Dp(16) over WT hippocampi of all 
independent experiments ± SEM, and circles represent the single data points of each independent 
experiment (1 animal per experiment). * p<0.05, ** p<0.01, *** p<0.001; Independent One-
Sample t-test against 0. (d) Representative immunoblots on protein extracts from lysates of 
hippocampi obtained from P22 WT and Dp(16) mice (left). Quantification of LAMP1 protein levels 
normalized to GADPH immunoreactivity (right). Bars represent the average percentage of LAMP1 
levels in Dp(16) over WT hippocampi for all analyzed animals ± SEM, and circles represent the 
single data points for each animal. *** p<0.001; Unpaired Two-tailed Student’s t-test, t=3.81, 
df=25. Data were collected from 5 independent experiments. (e) Representative single-plane 
confocal images of Iba1 (green) and LAMP1 (red)-stained hippocampal slices from P22 WT and 
Dp(16) animals, and the merging of the two channels showing Y-Z dimensions (left) and X-Z 
dimensions (up in WT and below in Dp(16)). Scale bar: 10μm. (f) Quantification of the LAMP1+ area 
normalized on Iba1+ area for microglial cell in experiments as in e. Bars represent the average 
LAMP1/Iba1 area for all analyzed animals ± SEM, and circles represent the average for all analyzed 
cells for each animal (4-9 cells/animal; 1 slice per animal). ** p=0.0038; Unpaired Two-tailed 




Figure 12. Cytokines are upregulated in Dp(16) animals. Quantification of the fold change of all 
the cytokines probed in vehicle-treated Dp(16) animals hippocampi when compared to vehicle-
treated WT animals from the same experiments in figure 11b. Bars represent the average 
percentage of cytokine levels in Dp(16) over WT hippocampi of all independent experiments ± 
SEM, and circles represent the single data points of each independent experiment (1 animal per 
experiment). Statistically significant cytokines are highlighted in red. * p<0.05, ** p<0.01, *** 
p<0.001; Independent One-Sample t-test against 0.  
 
The depletion of microglia recovers the cognitive deficits in Dp(16) mice 
Microglial activation induced by inflammatory challenges or occurring in aging correlates with a 
decreased cognitive performance (Shobin et al., 2017; Tang et al., 2018). Since microglial cells in 
the hippocampus of Dp(16) mice show characteristics of activated microglia, we reasoned that 
they could play a role in cognitive deficits, which have already been described in this strain 
(Goodliffe et al., 2016). Dp(16) mice are a fairly recent model of DS, which has not been 
characterized thoroughly. Among the behavioral tests addressing hippocampus-dependent 
learning and memory, only the Morris water maze and fear conditioning have been performed on 
Dp(16) animals (Yu et al., 2010). Although these tests did reveal poor performance of the trisomic 
mice, both tests can be stressful for the mice (Carpenter and Summers, 2009; O'Connor and 
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Chipkin, 1984). Since stress per se may cause microglial activation (Delpech et al., 2016), we 
subjected Dp(16) animals and their WT littermates to two less stressful hippocampus-dependent 
cognitive tests (i.e., the novel object recognition (NOR) and object location test (OLT); (Deidda et 
al., 2015; Parrini et al., 2017), which had never been described for Dp(16) before. We found that 
trisomic animals presented cognitive deficits in NOR and OLT tests compared to their WT 
littermates (Fig. 13a, e-f). Interestingly, when we ran a proteomic analysis on the hippocampi of 
P22 Dp(16) animals and WT littermates followed by gene ontology (GO) analysis on the 169 
differentially expressed proteins (Table 1), we found the term Memory among the first hits (Figure 
14a-b; Table 2). This is in agreement with the idea that the trisomy interferes with hippocampal 
functions, affecting learning and memory. 
To directly address whether defective microglia play a role in the low performance of Dp(16) mice 
in NOR and OLT, we took advantage of PLX3397. PLX3397 is a drug that selectively decreases the 
microglial population, without causing significant cognitive impairment in WT animals (Elmore et 
al., 2014). We thus treated P16 Dp(16) mice and their WT littermates with PLX3397 in their food 
supply (445 mg/kg of food available at libitum) for one week, and we then evaluated the impact of 
microglial depletion on cognitive performance at P22 (Fig. 13a). As expected, PLX3397 treatment 
sharply decreased the microglia count and Iba1 protein levels in the hippocampus of WT and 
Dp(16) mice (Fig. 13b-c). Remarkably, the treatment with PLX3397 fully rescued the cognitive 
deficit observed in the Dp(16) mice in the NOR and the OLT (Fig. 13e-f), supporting our hypothesis 
that activated microglia play a role in cognitive deficits.  
Altogether, these data indicate that depletion of activated microglia can ameliorate the cognitive 






Figure 13. PLX3397 treatment depletes microglia and rescues cognitive deficits in Dp(16) mice.  
(a) Experimental protocol used for PLX3397 treatment, histology/western-blotting and behavioral 
experiments. (b) Representative confocal images and higher magnifications from highlighted 
regions of Iba1-stained hippocampal slices from P22 WT and Dp(16) animals treated with either 
vehicle or PLX3397 in the chow. Scale bar: 100μm. (c) Quantification of the density of microglial 
cells in experiments as in b. Bars represent the average density of Iba1+ cells of all the analyzed 
animals ± SEM, and symbols represent the single data points for each animal (1 slice per animal). 
*** p<0.001; Two-Way ANOVA, FTreatment (1, 29) = 642.6, p < 0.001; Holm-Sidak post-hoc test. The 
vehicle-treated animal data (dotted circles) were taken from Fig. 8c and shown here for 
comparison. (d) Representative immunoblots on protein extracts from lysates of hippocampi 
obtained from P22 WT and Dp(16) mice treated with either vehicle or PLX3397 in the chow (left). 
Quantification of Iba1 protein levels normalized to GADPH immunoreactivity (right). Bars 
represent the average percentage of Iba1 levels over WT vehicle of all analyzed animals ± SEM, 
and symbols represent the single data points for each animal. *p<0.05, **p<0.01, ***p < 0.001; 
Two-Way ANOVA, FTreatment (1, 38) = 27.26, Holm-Sidak post-hoc test. Data were averaged across 6 
independent experiments. The vehicle-treated animal data (dotted circles) were taken from Fig. 
11a and shown here for comparison. (e) Quantification of the discrimination index in the novel 
object recognition test in P22 WT and Dp(16) mice following vehicle or PLX3397 treatment. Bars 
represent the average discrimination index of all analyzed animals ± SEM, and symbols represent 
the single data points for each animal. *p<0.05, **p<0.01; Two-Way ANOVA, FInteraction (2, 84) = 
11.52, p < 0.0001; Holm-Sidak post-hoc test. (f) Quantification of the discrimination index in the 
object location test in P22 WT and Dp(16) mice following vehicle or PLX3397 treatment. Bars 
represent the average discrimination index of all analyzed animals ± SEM, and symbols represent 
the single data points for each animal. *p<0.05, **p<0.01; Two-Way ANOVA, FInteraction (2, 52) = 








Figure 14. Proteomics analysis revealed differences in biological processes in hippocampi from 
Dp(16) mice. (a) Volcano plot depicting all the proteins (169) that were identified in the 
hippocampi of P22 WT and Dp(16) mice by proteomic analysis. The red dots represent the proteins 
that are significantly downregulated (Student’s t test difference < 0) or upregulated (Student’s t 
test difference > 0) in the hippocampus of Dp(16) compared to WT mice. The data were collected 
from 5 animals for each group. (b) Gene ontology terms on biological processes that are 
significantly altered in the hippocampi of Dp(16) vs WT mice. A p-value threshold of 0.05 was 
applied. The numbers on top of the histograms indicate the number of dysregulated proteins that 
generate the difference. 
 
Microglial depletion restores the levels of the dendritic spine protein drebrin and rescues 
dendritic spine number and function in the hippocampus of Dp(16) mice 
Since microglia play a crucial role in spine dynamics and in the synaptic elimination that occurs 
during plasticity (Garre et al., 2017; Miyamoto et al., 2016; Wu et al., 2015), we reasoned that the 
overactive microglia of the Dp(16) mice could impair the cognitive performance of Dp(16) animals 
by affecting the number and/or the level of maturation of spines. To test this hypothesis, we first 
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turned our attention to a dendritic spine marker, drebrin (DBN), which is downregulated by the 
activation of microglia (Kojima and Shirao, 2007; Ma et al., 2015; Xing et al., 2011) and it is 
decreased in brains of subjects with DS and in Alzheimer’s disease (Kojima and Shirao, 2007; Ma et 
al., 2015; Xing et al., 2011). By western blotting with a specific antibody against DBN, we observed 
significantly decreased levels of this protein in the hippocampi of P22 Dp(16) mice in comparison 
to WT mice (Fig. 15a). Accordingly, when we ran a targeted proteomic protocol on hippocampi 
from Dp(16) and WT littermates, we found a sharp decrease in the levels of 4 different peptide 
fragments ascribed to DBN in trisomic mice (Figure 16a-b). Interestingly, PLX3397 treatment 
completely rescued the drebrin levels in Dp(16) mice, as assessed by western blotting (Fig. 15a). In 
agreement with our hypothesis, we found a decreased number of spines in CA1 hippocampal 
excitatory pyramidal neurons from Dp(16) mice counted after Golgi-Cox staining, which was fully 
rescued by the PLX3397 treatment (Fig. 15b-c). In particular, PLX3397 treatment had a significant 
effect on motile spines with a full rescue of the density of the thin-type (Majewska and Sur, 2003) 
in Dp(16) mice. Moreover, PLX3397 partially rescued the density of fully mature mushroom-type 
(Majewska and Sur, 2003) spines in Dp(16) mice and had no effect on immature spines (Figure 
16a-c). Finally, depletion of microglial cells by PLX3397 treatment fully rescued the frequency and 
amplitude of miniature excitatory postsynaptic currents (mEPSCs; Fig. 15d-e), which suggests that 
the defective trisomic microglia also impinges on the correct functionality of dendritic spines. An 
increased number of contacts between microglia and synaptic elements is considered to be 
indicative of augmented synaptic elimination (Sipe et al., 2016). Thus, to further confirm that the 
overactive microglia in Dp(16) animals regulated the number of neuronal spines, we turned to 
electron microscopy. In P22 Dp(16) mice, we observed an increased number of contacts between 
microglia and surrounding cells -and specifically synaptic elements- compared to WT animals (Fig. 
15f-g and Figure 17d).  
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Taken together, these data suggest that overactive microglia cause altered dendritic spine 




Figure 15. Drebrin levels, dendritic-spine density and miniature postsynaptic events are altered, 
and rescued by PLX3397 treatment in Dp(16) mice. (a) Representative immunoblots on protein 
extracts from lysates of hippocampi obtained from P22 WT and Dp(16) mice (left). Quantification 
of Drebrin protein levels normalized to GADPH immunoreactivity (right). Bars represent the 
average percentage of Drebrin levels in Dp(16) over WT hippocampi for all analyzed animals ± 
SEM, and symbols represent the single data point for each animal. ** p<0.01, *** p<0.001; Two-
Way ANOVA, FInteraction (1, 39) = 7.166, p = 0.0108; Holm-Sidak post-hoc test. Data were averaged 
across 6 independent experiments. (b) Representative light-transmitted images of dendritic spines 
from Golgi-Cox-stained slices of hippocampi from P22 WT and Dp(16) mice treated with vehicle or 
PLX3397. Scale bar: 4µm. (c) Quantification of the spine density in experiments as in b. Bars 
represent the average spine density of all analyzed cells ± SEM, and symbols represent the single 
data points for each cell (3 animals per condition). *** p<0.001; Two-Way ANOVA, FInteraction (1, 51) 
= 20.84, p < 0.0001; Holm-Sidak post-hoc. (d) Representative traces of mEPSC recordings in CA1 
hippocampal pyramidal neurons from P22 WT and Dp(16) mice treated with vehicle or PLX3397. 
Scale bars: 10pA and 1s. (e) Quantification of the mEPSC frequency (left) and amplitude (right) in 
experiments as in d. Bars represent the average frequency and the average amplitude for all 
analyzed cells ± SEM, and symbols represent the single data points for each cell (3 WT vehicle-
treated animals and 4 animals per each remaining conditions). *** p<0.001; For frequency: Two-
Way ANOVA, FInteraction (2, 86) = 14.09, p < 0.0001; For amplitude Two-Way ANOVA, FInteraction (2, 86) 
= 20.61, p < 0.0001; Holm-Sidak post-hoc test. (f) Representative transmission electron microscopy 
images of hippocampal slices from P22 WT and Dp(16) mice. Scale bar: 500 nm. m: microglia, a: 
astrocytes, d: dendrite shaft, t: pre-synaptic element, s: post-synaptic element. (g) Quantification 
of the interaction between microglia and dendritic spines in experiments as in f. Bars represent 
the average number of contact points between microglia and spines of all animals analyzed ± SEM, 
and circles represent the average of all analyzed fields for each animal (20-44 fields/animal). 




Figure 16. Proteomics analysis showed defects in the Drebrin protein levels in hippocampi from 
Dp(16) mice. (a) Heat-map from proteomic experiments of the peak area normalized to the 
maximum peak of Drebrin for the four peptides that can be ascribed to Drebrin (vertical columns). 
The data were collected from 7 animals per genotype (horizontal lines). (b) Quantification of the 
normalized peak area for each animal from experiments in a. For each animal, the reads from each 
peptide were summed together. Bars represent the average sum of the peak area of all analyzed 
animals ± SEM, and circles represent the single data points for each animal **p<0.01; Unpaired 





Figure 17. PLX3397 or APAP treatment rescues specific types of dendritic spines in Dp(16) mice. 
(a) Cartoon depicting the morphological characteristics of immature, filopodia spines (top). 
Quantification of the filopodia spine density (bottom) in P22 WT and Dp16 animals treated with 
vehicle, PLX3397, or APAP from experiments in Fig. 15c and Fig. 21a. Bars represent the average 
filopodia spine density of all analyzed cells ± SEM, and symbols represent the single data points for 
each cell. Data were collected from 3 animals per condition. (b) Cartoon depicting the 
morphological characteristics of the functional and motile, thin and stubby spines (top). 
Quantification of the thin or stubby spine density (bottom) in P22 WT and Dp16 animals treated 
with vehicle, PLX3397, or APAP from experiments in Fig. 15c and Fig. 21a. Bars represent the 
average thin or stubby spine density of all analyzed cells ± SEM, and symbols represent the single 
data points for each cell. For thin spines: ** p<0.01, *** p<0.001; Two-Way ANOVA FInteraction (2, 
79) = 13.92, p<0.001. For stubby spines: **p<0.01; Two-Way ANOVA FTreatment(2, 79) = 18.98, 
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p<0.001; Holm-Sidak post-hoc test. Data were collected from 3 animals per condition. (c) Cartoon 
depicting the morphological characteristics of the functional and stable, mushroom spines (top). 
Quantification of the mushroom spine density (bottom) in P22 WT and Dp16 animals treated with 
vehicle, PLX3397, or APAP from experiments in Fig. 15c and Fig. 21a. Bars represent the average 
mushroom spine density of all analyzed cells ± SEM, and symbols represent the single data points 
for each cell. * p<0.05, ** p<0.01; Two-Way ANOVA, FInteraction (2, 79) = 6.915, p = 0.0017; Holm-
Sidak post-hoc test. Data were collected from 3 animals per condition. (d) Quantification of the 
number of physical interactions between the microglia and the pre-synaptic (left) or the post-
synaptic (right) elements from experiments in Fig. 15f. Bars represent the average number of 
physical interactions between the microglia and the pre-synaptic or the post-synaptic element ± 
SEM in all analyzed animals, and circles represent the average of all the analyzed fields for each 
animal (Presynaptic interactions (20-44 fields/animal): *p<0.05; Unpaired Two-tailed Student’s t-
test, t=3.14, df=5. Post-synaptic interactions (20-44 fields/ animal): *p<0.05; Unpaired Two-tailed 
Student’s t-test, t=3.09, df=5. 
 
APAP treatment rescues microglial morphology, decreases cytokine levels and rescues spine 
density in the hippocampus of Dp(16) mice 
Recent evidence in brains from the Ts65Dn mouse model of DS and from subjects with DS 
indicates increased expression of the inducible form of the cyclooxygenase enzymes (COX2) in 
microglia and neurons, which is a sign of increased immunological activity (Mulet et al., 2017). 
Indeed, activated microglia produce a large amount of the pro-inflammatory molecule PGE2 
(Zhang et al., 2009). Because COX2 inhibitors can decrease the production of PGE2 by microglia 
(Villa et al., 2016; Zhang et al., 2009) decreasing overall inflammation, we hypothesized that the 
use of a COX2 inhibitor could rescue the microglial phenotype in Dp(16) mice. Among COX2 
inhibitors, we chose to use APAP because it is one of the most widely used COX2 inhibitors; it 
readily crosses the blood-brain barrier and it has a very safe profile with few contraindications. 
Remarkably, after three daily doses of APAP (IP, 100 mg/kg, Fig. 18a), we completely rescued the 
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microglial morphology, measured as the cell-body area (Fig. 18b-c) and ramifications (Fig. 18d-g) in 
the hippocampi of Dp(16) mice at P22. APAP treatment also rescued the microglia cell body area in 
the somatosensory cortex (Fig. 19a-c). Importantly, APAP treatment also decreased the levels of 
all overrepresented cytokines in the Dp(16) mouse hippocampi (Fig. 18h, Fig. 20a-b). Interestingly, 
we were able to fully rescue the spine density with APAP treatment, with a full rescue of the 
mature mushroom-type and a partial rescue of motile thin-type in Dp16 mice (Fig. 21a-b, Fig. 17b-
c). Accordingly, APAP treatment also rescued the frequency and amplitude of mEPSCs in Dp(16) 
animals (Fig. 21c-d). 
Taken together, our data indicate that APAP treatment in Dp(16) animals is able to recover the 
activity state of microglia together with spine density and function, further strengthening the 










Figure 18. Acetaminophen (APAP) treatment rescues microglial morphology and cytokine levels 
in Dp(16) mice. (a) Experimental protocol used for APAP treatment and histology/western-
blotting. (b) Representative confocal images of Iba1-stained hippocampal slices from WT and 
Dp(16) animals treated with either vehicle or APAP. Scale bar: 10μm. (c) Quantification of the cell 
body area of microglial cells in experiments as in b. Bars represent the average of microglial cell 
body areas in all analyzed animals ± SEM and circles represent the single data points of the cell 
averages for each animal (14-73 cells/ animal; 1 slice per animal). * p<0.05; Two-Way ANOVA 
FInteraction (1, 23) = 14.88 p = 0.0008; Holm-Sidak post-hoc test. The vehicle-treated animal data 
(dotted circles) were taken from Fig. 8d and shown here for comparison. (d) Binary images of the 
fields shown in b. Scale bar: 10μm. (e) Sholl analysis of microglial cells in images as in d. Data are 
expressed as average number of intersections at each distance from the cell bodies of all analyzed 
cells ± SEM. Numbers in parenthesis: analyzed cells, and animals. The vehicle-treated WT animal 
data were taken from Fig. 8g and shown here for comparison. (f) Sholl analysis of microglial cells in 
images as in d. Data are expressed as average number of intersections at each distance from the 
cell bodies of all analyzed cells ± SEM. Numbers in parenthesis: analyzed cells, and animals. *** 
p<0.001; Two-Way ANOVA, FTreatment (1, 6426) = 58.32, p < 0.0001; Holm-Sidak post-hoc test. The 
vehicle-treated WT animal data were taken from Fig.8g and shown here for comparison. (g) 
Quantification of the median distance of the intersections from the cell body, as obtained from 
the Sholl analysis in f. Bars represent the average of the median distances in all analyzed animals ± 
SEM, and circles represent the single data points of the median distance averages for each animal 
(12-21 cells/animal; 1 slice per animal). * p<0.05, Two-Way ANOVA, FInteraction (1, 17) = 17.41, p = 
0.0006; Holm-Sidak post-hoc test). The vehicle-treated animal data (dotted circles) were taken 
from Fig. 8h and shown here for comparison. (h) Quantification of the rescue effect of APAP 
treatment (red) on all the cytokines significantly increased in Dp(16) vs WT hippocampi (black). 
Bars represent the average percentage of cytokine levels in APAP- or vehicle-treated Dp(16) 
hippocampi over WT hippocampi and of all independent experiments ± SEM, and circles represent 
the single data points of each independent experiment (1 animal per experiment). Two-Way 
ANOVA, FTreatment (1, 90) = 20.47, p < 0.001. The data of vehicle-treated Dp(16) animals normalized 





Figure 19. APAP treatment rescues microglial morphology in the somatosensory cortex of Dp(16) 
mice. (a) Experimental protocol used for APAP treatment and for analyzing the morphology of 
microglia. (b) Representative confocal images of Iba1-stained somatosensory cortices from P22 
WT and Dp(16) animals treated with either vehicle or APAP. Scale bar: 20μm. (c) Quantification of 
the cell body area of microglial cells in experiments as in b. Bars represent the average of 
microglial cell body areas in all analyzed animals ± SEM and circles represent the single data points 
of the cell averages for each animal (72-126 cells/animal; 1 slice per animal). **p<0.01, *** 
p<0.001; Two-Way ANOVA FInteraction (1, 19) = 13.19, p = 0.0018; Holm-Sidak post-hoc test. The 











Figure 20. APAP affects cytokines levels. (a) Quantification of the fold change of all the cytokines 
probed in APAP-treated Dp(16) animals hippocampi when compared to vehicle-treated WT 
animals from the same experiments in Fig. 18g. Bars represent the average percentage of cytokine 
levels in APAP-treated Dp(16) over WT hippocampi of all independent experiments ± SEM, and 
circles represent the single data points of each independent experiment (1 animal per 
experiment). Statistically significant cytokines are highlighted in red. * p<0.05; Independent One-
Sample t-test against 0. (b) Quantification of the fold change of all the cytokines probed in APAP-
treated WT animals hippocampi when compared to vehicle-treated WT animals from the same 
experiments in figure 18g. Bars represent the average percentage of cytokine levels in APAP-
treated WT over vehicle-treated WT animals of all independent experiments ± SEM, and circles 




Figure 21. APAP rescues spine and electrophysiological deficits. (a) Representative light-
transmitted images of dendritic spines from Golgi-Cox-stained slices of hippocampi from P22 WT 
and Dp(16) mice treated with vehicle or APAP. Scale bar: 4µm. (b) Quantification of the spine 
density in experiments as in a. Bars represent the average spine density of all analyzed cells ± SEM, 
and circles represent the single data points for each cell (3 animals per condition). *** p<0.001; 
Two-Way ANOVA, FInteraction (1, 56) = 42.99, p<0.001; Holm-Sidak post-hoc test. The vehicle-treated 
cell data (dotted circles) were taken from Fig. 15c and shown here for comparison. (c) 
Representative traces of mEPSC recordings in CA1 hippocampal pyramidal neurons from P22 WT 
and Dp(16) mice treated with vehicle or APAP. Scale bars: 10pA and 1s. (d) Quantification of the 
mEPSC frequency (left) and amplitude (right) in experiments as in d. Bars represent the average 
frequency and the average amplitude of mEPSCs for all analyzed cells ± SEM, and circles represent 
the single data points for each cell (4 Dp(16) vehicle-treated animals and 3 animals per each 
remaining condition). *p<0.05, ** p<0.01, *** p<0.001); For frequency: Two-Way ANOVA, 
FInteraction(1, 57) = 18.51, p<0.001; For amplitude Two-Way ANOVA, FInteraction (1, 57) = 38.21, 
p<0.001; Holm-Sidak post-hoc test). The vehicle-treated animal data (dotted circles) were taken 
from Fig. 15e and shown here for comparison. 
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Acetaminophen treatment rescues cognitive deficits in Dp(16) mice and have opposite effects in 
WT mice 
Our results on the rescue of cognitive impairment in Dp(16) mice upon depletion of microglia 
strongly suggest that these cells regulate learning and memory in trisomic animals. Thus, we 
investigated whether not only the complete depletion, but also the simple rescue of the activation 
state of microglia in Dp(16) mice was sufficient to restore their cognitive abilities. Thus, we treated 
Dp(16) and WT littermates with APAP from P20 to P22 and performed the NOR and OLT cognitive 
tests. APAP treatment completely recovered the cognitive deficits in Dp(16) animals (Figure 22a-c). 
In agreement with a hindering role of activated microglia in the cognitive abilities of Dp(16) mice, 
the administration of an inhibitor of the JAK1/2 pathway (ruxolitinib; 50 mg/kg twice a day for 3 
consecutive days), whose activation is important for microglial activation (Qin et al., 2016), 
significantly rescued microglial branching (Figure 23a-g) together with cognitive performance in 
Dp(16) mice (Figure 23h-i). Notably, in WT animals, the treatment with APAP caused a decreased 
cognitive performance in both the NOR and OLT tests, together with a more amoeboid microglial 
morphology, and a significant decrease in the number of neuronal spines as well as in the mEPSC 
amplitude, but no significant effect on cytokine levels (Fig. 20; Fig. 21). These results indicate that 
the effects of APAP might be dependent on the genotype and that the behavioral cognitive 
outcome is strongly correlated with the microglia activated morphology as well as the spine 
density and function. 
Altogether, our results indicate that APAP treatment influences spine density and function as well 
as cognitive performance, and that recovery of microglial activation state can have a positive 






Figure 22. APAP treatment rescues cognitive deficits in Dp(16) mice. (a) Experimental protocol 
used for APAP treatment, histology and electrophysiology. (b) Quantification of the discrimination 
index in the novel object recognition test in P22 WT and Dp(16) mice following vehicle or APAP 
treatment. Bars represent the average discrimination index of all analyzed animals ± SEM, and 
circles represent the single data points for each animal. *p<0.05, **p<0.01; Two-Way ANOVA, 
FInteraction (1, 51) = 23.76, p<0.001; Holm-Sidak post-hoc test. The vehicle-treated animal data 
(dotted circles) were taken from Fig. 13e and shown here for comparison (c) Quantification of the 
discrimination index in the object location test in P22 WT and Dp(16) mice following vehicle or 
APAP treatment. Bars represent the average discrimination index of all analyzed animals ± SEM, 
and circles represent the single data points for each animal. * p<0.05, ** p<0.01; Two-Way 
ANOVA, FInteraction (1,35) = 11.24, p<0.002; Holm-Sidak post-hoc test. The vehicle-treated animal 







Figure 23. Ruxolitinib treatment rescues cognitive deficits and partially rescues microglial 
alterations in Dp(16) mice. (a) Experimental protocol used for Ruxolitinib treatment, and for 
analyzing the morphology of microglia and the behavior of mice. (b) Representative confocal 
images of Iba1-stained hippocampal slices from P22 WT and Dp(16) animals treated with either 
vehicle or Ruxolitinib. Scale bar: 20μm. (c) Quantification of the cell body area of microglial cells in 
experiments as in b. Bars represent the average of microglial cell body areas in all analyzed 
animals ± SEM and circles represent the single data points of the cell averages for each animal (38-
73 cells/animal; 1 slice per animal). * p<0.05, **p<0.01; Two-Way ANOVA FStrain (1, 24) = 17.35, p = 
0.0003; Holm-Sidak post-hoc test. The vehicle-treated animal data (dotted circles) were taken 
from Fig. 8d and shown here for comparison. (d) Binary images of the fields shown in b. Scale bar: 
20μm. (e) Sholl analysis of microglial cells in images as in d. Data are expressed as average number 
of intersections at each distance from the cell bodies of all analyzed cells ± SEM. * p<0.05, ** 
p<001; Two-Way ANOVA, F (33, 7140) = 3.352, p < 0.001; Holm-Sidak post-hoc test. Numbers in 
parenthesis: analyzed cells, and animals. The vehicle-treated WT animal data were taken from Fig. 
8g and shown here for comparison. (f) Quantification of the median distance of intersections from 
the cell body, as obtained from the Sholl analysis in e. Bars represent the average of the median 
distances in all analyzed animals ± SEM, and circles represent the single data points of the median 
distance averages for each animal (12-21 cells/animal; 1 slice per animal). * p<0.05, **p<0.01; 
Two-Way ANOVA, FInteraction (1, 21) = 4.392, p = 0.048; Holm-Sidak post-hoc test). The vehicle-
treated animal data (dotted circles) were taken from Fig. 8h and shown here for comparison. (g) 
Quantification of the number of branches per microglial cell in images as in d processed as in Fig 
8i. Bars represent the average number of branches per microglial cell ± SEM of all analyzed 
animals, and circles represent the single data points of the cell averages for each animal (12-21 
cell/animal; 1 slice per animal). * p<0.05, ** p<0.01; Two-Way ANOVA, FInteraction (1, 21) = 4.880 p = 
0.0384, Holm-Sidak post-hoc test. The vehicle treated animals data was taken from Fig. 8j and 
shown here for comparison. (h) Quantification of the discrimination index in the novel object 
recognition test in P22 WT and Dp(16) mice following vehicle or Ruxolitinib treatment. Bars 
represent the average discrimination index of all analyzed animals ± SEM, and circles represent the 
single data points for each animal. **p<0.01, ***p<0.001; Two-Way ANOVA, FInteraction (1, 33) = 
8.417, p=0.0066; Holm-Sidak post-hoc test. (i) Quantification of the discrimination index in the 
object location test in P22 WT and Dp(16) mice following vehicle or Ruxolitinib treatment. Bars 
represent the average discrimination index of all analyzed animals ± SEM, and circles represent the 
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single data points for each animal. **p<0.01; Two-Way ANOVA, FInteraction (1, 19) = 9.103, p=0.007; 
Holm-Sidak post-hoc test.  
 
Microglial defects are also present in the brains of persons with DS 
To verify whether our findings reflect the human condition, we analyzed the state of microglial 
activation in postmortem hippocampi from individuals with DS and age-matched controls (Table 
3). We first investigated the expression of Iba1 as a marker of microglia activation (Arcuri et al., 
2017; Hanisch and Kettenmann, 2007; Sipe et al., 2016) via western blot. We found increased 
expression of Iba1 in brain lysates from hippocampi of individuals with DS compared to controls 
(Fig. 24a), reflecting our findings in the Dp(16) mice (Fig. 11a). Next, to visualize the morphology of 
microglia, we took advantage of immunohistochemistry and stained brain slices from another set 
of individuals with DS and age-matched controls with an Iba1 antibody. This allowed us to perform 
the same analysis of microglial morphology already performed with Dp(16) animals (Fig. 8). 
Remarkably, we found that human DS microglia had enlarged cell bodies and, similar to Dp(16) 
animals, the enlargement concerned the whole microglial population (Fig. 24b-d). Moreover, the 
Sholl analysis revealed that human DS microglia also had ramification deficits (Fig. 24e), again in 
agreement with data in Dp(16) mice. A subsequent skeleton analysis revealed a decreased number 
of ramifications (Fig. 24f), which were, however, longer on average (Fig. 24g). 
Altogether, these results suggest that the microglial dysfunction observed in Dp(16) mice is also 








Figure 24. Microglial alterations are present in brains from persons with DS. (a) Representative 
immunoblots on protein extracts from lysates of hippocampi obtained from age and sex-matched 
controls and persons with DS (left). Quantification of Iba1 protein levels normalized to Actin 
immunoreactivity (right). Bars represent the average percentage of Iba1 levels in DS over control 
hippocampi in all individuals ± SEM, and circles represent the single data points for each person. 
Data were averaged across 3 independent experiments. * p = 0.027; Unpaired One-tailed Mann 
Whitney test U=3. (b) Representative confocal images of Iba1-stained hippocampal slices from a 
control and an individual with DS with no signs of amyloid deposition nor diagnosis of Alzheimer’s 
disease (individual 13202 in Supplementary Table 3). Scale bar: 20μm. (c) Quantification of the cell 
body area of microglial cells in experiments as in b. Bars represent the average of the microglia cell 
body areas of all analyzed individuals ± SEM, and circles represent the single data points of the cell 
averages for each individual (24-60 cells, 3-7 slice per individual). Red circles represent people with 
hippocampal signs or diagnosis of Alzheimer’s disease, as defined in Table 3. * p = 0.0423; 
Unpaired One-tailed Student’s T-test, t=1.83, df=17. (d) Cumulative distribution of the microglial 
cell body area of all analyzed cells, calculated as the percentages of the cells inside each bin area. 
The two distributions are significantly different (Kolmogorov-Smirnov Test, p<0.001). Numbers in 
parenthesis: number of cells, and number of individuals analyzed. (e) Sholl analysis of microglial 
cells in images as in b processed as in Fig. 8f. Data are expressed as average number of 
intersections at each distance from the cell bodies of all analyzed cells ± SEM. The statistical 
analysis revealed a significant effect of the diagnosis of DS (Two-Way ANOVA, FDiagnosis (1, 1443) = 
38.64, p < 0.0001). Numbers in parenthesis: cells, and analyzed individuals (4-10 slices per 
individual). Only slices from individuals 13149, 13202, 13235 and 13250 as in Table 3 had sufficient 
quality of Iba1 1 staining to ensure correct analysis of microglial ramifications and were analyzed. 
(f) Quantification of the number of branches per microglial cell in images as in b processed as in 
Fig. 8i. Bars represent the average number of branches per microglial cell ± SEM in all analyzed 
individuals, and circles represent the single data points of the cell averages for each individual (9-
10 cell/individual; 4-10 slices per individual from the same individuals in e). * p<0.05; Unpaired 
One-tailed Mann-Whitney test, U=115. (g) Quantification of the average length of branches per 
microglial cell in images as in b processed as in Fig 8i. Bars represent the average of branch length 
per microglial cell ± SEM in all analyzed individuals, and circles represent the single data points of 
the cell averages for each individual (9-10 cells/individual; 4-10 slices per individual from the same 




Microglial activation in DS 
Recent evidence has indicated a high overall level of inflammation (Sullivan et al., 2017) and a high 
incidence of hematological and autoimmune diseases in DS (Alexander et al., 2016; Kinik et al., 
2006). This is due to increased levels of circulating pro-inflammatory molecules, which is 
particularly marked in the brain (Wilcock and Griffin, 2013). Signs of high inflammation have also 
been observed in animal models of DS (Fructuoso et al., 2018; Gally et al., 2018; Guedj et al., 
2015). However, a detailed investigation of microglia and their role in cognition in DS is still 
lacking. To address this issue in DS animal models, we preferred the Dp(16) mouse to the more 
commonly used Ts65Dn mouse. Indeed, contrary to Ts65Dn mice, Dp(16) mice do not show 
marked prenatal signs of defective neuronal precursor proliferation and neurogenesis (Goodliffe 
et al., 2016). These are per se a cause of cognitive defects in Ts65Dn mice (Parrini et al., 2017) and 
could be a confounding factor when investigating the role of microglia in cognitive performance. 
Indeed, we hypothesize that the alerted microglial phenotype we observed in Dp(16) might be 
exacerbated in Ts65Dn due to the increased amount of neuronal precursors phagocyted during 
development. We focused our investigation mostly on the hippocampus of Dp(16) mice, as 
microglia play a pivotal role in the correct formation and function of the hippocampus in WT 
animals (Riazi et al., 2015; Sierra et al., 2010; Tremblay et al., 2011), and this structure is strongly 
altered in DS (Alldred et al., 2018; Parrini et al., 2017; Raveau et al., 2018; Vacano et al., 2018; 
Velazquez et al., 2013). In addition, extensive evidence in the literature exists that hippocampal-
related cognitive functions are the most impaired in people and animal models of DS (Deidda et 
al., 2015; Parrini et al., 2017). Here, we further characterized hippocampal cognitive function in 
the poorly investigated Dp(16) mouse. We restricted our investigation to the third postnatal week 
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of life (P22) because the main postnatal developmental stages are completed, but the brain still 
retains a good level of plasticity at this age (Le Magueresse and Monyer, 2013; Zhang, 2004). 
At P22, the microglia in the Dp(16) hippocampus showed morphological signs of activation, such 
as enlarged cell bodies and decreased ramifications, when compared to those of WT littermates. 
This observation is consistent with the defects in microglial activation and branching area that 
have been previously described in Ts65Dn mice (Hunter et al., 2004; Mulet et al., 2017; Rueda et 
al., 2018). In Dp(16) mice, we also observed an active microglial phenotype in the somatosensory 
cortex, although to a milder extent than in the hippocampus. This could be due to the different 
gene expression profiles of the microglial populations residing in the two brain regions. Indeed, 
hippocampal microglia exist in a more immune vigilant state than their cortical counterparts 
(Grabert et al., 2016). Therefore, the hippocampal microglial population could possibly respond 
more strongly to the increased level of inflammation observed in DS (Broers et al., 2014; Fructuoso 
et al., 2018; Gally et al., 2018; Sullivan et al., 2017). Interestingly, microglial pathology (i.e., 
increased activation) is also present in other neurodevelopmental disorders, such as Rett 
Syndrome, autism and schizophrenia (Salter and Stevens, 2017). Indeed, elimination of the CX3CR1 
signaling (and therefore altering microglia only) generates strong autistic-like behaviors.  
Furthermore, in agreement with the idea that the peculiar morphology of the trisomic microglia is 
reflective of an activated state due to chronic inflammation in DS, we found increased levels of 
Iba1, cytokines and LAMP1 in the hippocampus of Dp(16) mice. Iba1 is a calcium-binding protein 
that is constitutively expressed by resting microglia. However, its expression is increased in 
concomitance with cytoskeletal remodeling and the consequent changes in cell morphology that 
occur during microglial activation. Thus, Iba1 is a reliable marker of microglia activation (Bosco et 
al., 2011; Imai and Kohsaka, 2002; Nilsson et al., 2008).  
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The overexpression of Iba1 was accompanied by increased levels of cytokines normally secreted 
by activated microglia, such as IL-1β and IL-6 (Wang et al., 2015). Interestingly, although the vast 
majority of the cytokines we found upregulated in the hippocampi of Dp(16) mice were pro-
inflammatory, two anti-inflammatory cytokines (i.e., IL-4 and IL-10) were also upregulated. 
Notably, an increased production of IL-10, as a reaction to a chronic inflammatory state, has been 
described in subjects with DS (Broers et al., 2014). This observation also suggests that aberrant 
control of the production of anti-inflammatory molecules is present in DS, which contributes to 
the overall immunological dysregulation. In agreement with our findings, increased IL-1β and IL-6 
can strongly alter hippocampal, LTP possibly acting through microglia activation (Riazi et al., 2015). 
However, we failed to detect any expression of the classical microglial activation marker MHCII 
(Hayes et al., 1987) in Dp(16) mice. Still, this is not the only example of microglial activation in the 
absence of increased expression of MHCII (Sipe et al., 2016). For instance, the same happens 
during the microglia-dependent synaptic elimination necessary for critical-period plasticity (Sipe et 
al., 2016). Moreover, a non-canonical activation of microglia is also caused by increased neuronal 
firing, which leads to changes in microglial morphology and physiology with no activation of MHCII 
(Hung et al., 2010; Kierdorf and Prinz, 2013; Sipe et al., 2016). Interestingly, in the Ts65Dn mouse, 
GABA signaling contributes to increased excitability of the hippocampus (Deidda et al., 2015). This 
increased level of excitability could lead to the morphological changes described in the literature 
in Ts65Dn mice and to the MHCII-independent microglial morphology alterations and increased 
activation markers described here in the Dp (16) mice. Nevertheless, whether GABAergic signaling 
positively regulates hippocampal excitability in Dp(16) mice is still unknown. 
In agreement with the elevated levels of Iba1 and pro-inflammatory cytokines indicative of 
microglia activation, we also found increased levels of LAMP1. LAMP1 is a protein that is highly 
expressed in lysosomes and is upregulated when there is an increase in phagocytosis (Maxfield 
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and McGraw, 2004) in several cell types, including activated microglia (Tanaka et al., 2013). 
Interestingly, very prominent defects in the lysosomal pathways were observed in DS (Colacurcio 
et al., 2018).  
Microglia, synaptic  elimination and cognitive impairment in DS 
Dendritic spine dynamics are necessary for learning and memory (Bosch et al., 2014; Salter and 
Stevens, 2017). Interestingly, recent evidence indicated that microglia play a pivotal role in 
remodeling dendritic spines and regulate their activity in brain development and plasticity (Kaur et 
al., 2017; Salter and Stevens, 2017). Moreover, individuals with DS and DS animal models (i.e., Tc1, 
Ts1Rh1, Ts65Dn and Ts1Cje mice (Belichenko et al., 2009; Haas et al., 2013; Herault et al., 2017; 
Torres et al., 2018) present altered spine density possibly due to increased synaptic  elimination 
(Phillips and Pozzo-Miller, 2015). This experimental evidence prompted us to hypothesize that the 
link between the microglial changes observed in Dp(16) mice and their cognitive deficits may be 
the action of the hyperactive microglia on dendritic spines. Remarkably, the depletion of defective 
microglia from the brain parenchyma via administration of PLX3397 rescued the dendritic spine 
number of the functional subtypes, thin and mushroom (Majewska and Sur, 2003; Xu et al., 2018), 
together with the cognitive performance in Dp(16) mice. Consistently, PLX3397 treatment fully 
rescued the amplitude and frequency of mEPSCs, which we found altered in Dp(16) mice. Even if 
the mushroom spine density was not fully rescued, the mESPCs rescue can be explained by the 
fact that thin spines are also electrophysiologically active. Indeed, thin spines are also nicknamed 
“learning spines” because they are highly mobile and likely to change shape in response to activity, 
whereas mushroom spines, also called “memory spines,” are less mobile and more stable (Peebles 
et al., 2010) Notably, deficits in mEPSCs were observed in a wide number of animal models of 
neurodevelopmental disorders characterized by high inflammation levels and spine defects such 
as autism (Wu et al., 2018), Fragile X syndrome (Scharkowski et al., 2018), and Rett syndrome (Xu 
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and Pozzo-Miller, 2017) as well as the Ts65Dn mouse model of DS (Parrini et al., 2017). Moreover, 
microglial activation with LPS (a powerful microglia activator; (Chang et al., 2015) elicits deficits in 
mEPSCs together with a decrease in spine density. Thus, our results together with the literature 
indicate a relationship between microglial over-activation, spine impairments and cognitive 
disability in DS and suggest that similar microglia-dependent spine  elimination may occur in other 
neurodevelopmental disorders. Interestingly, in a recent study Spangenberg et al. showed that 
depletion of microglia by PLX3397 treatment was able to rescue dendritic spine loss and neuronal 
death together with an overall decrease of neuroinflammation and increase in cognitive 
performance in a mouse model of AD. This could suggest that microglia may be a target for 
therapeutic intervention not only in young DS adults, but also later in life when these individuals 
become prone to developing AD (Spangenberg et al., 2016).  
We decided to use drebrin (DBN) as a proxy to study spine density as previously done by other 
groups (Weitzdoerfer et al., 2001). DBN is an actin-binding protein highly expressed in spines 
where it exerts a pivotal role in maintenance and maturation, and its levels are drastically 
decreased in individuals with DS (Shim and Lubec, 2002; Weitzdoerfer et al., 2001) and during 
inflammation (Rao et al., 2012; Weitzdoerfer et al., 2001). Indeed, the activation of microglia with 
LPS in microglia-neuron co-cultures led to an extensive decrease in DBN levels in neurons (Xing et 
al., 2011). Moreover, decreased levels of DBN in experimental animals and in neurons in vitro 
caused a decrease in the density of spines and a shift toward more immature spinal states 
(Koganezawa et al., 2017; Rao et al., 2012; Takahashi et al., 2006). Accordingly, we found a 
significant decrease in the level of DBN accompanied by a decrease in the overall spine density, 
and particularly functional spines (thin, mushroom types; (Risher et al., 2014) in Dp(16) mice. The 
level of expression of DBN together with the spine density and the cognitive impairment were 
rescued upon depletion of the aberrant microglia by treatment of trisomic animals with PLX3397. 
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This result together with the increased interaction between microglia and spine elements we 
observed by electron microscopy in Dp (16) mice and the increased LAMP1 expression (i.e., 
increased phagocytic activity of trisomic microglia) sustain our hypothesis that the higher 
activation state of microglia leads to abnormal synaptic elimination of dendritic spines that in turn 
causes cognitive deficits in trisomic animals.  
Additionally, the hippocampal proteome analysis we performed in Dp(16) and WT mice supports 
the idea that the difference in the cognitive behavior between the two strains may depend on a 
defect in spine elimination. Indeed, among the differentially expressed proteins, we singled out 4 
significant proteins that fall into the gene ontology (GO) Memory category (i.e., integrin alpha 3 
(Itga3), sodium/calcium exchanger member 3 (Slc8a3), sortilin-related VPS10 domain containing 
receptor 3 (Sorcs3) and kalirin (Kln)) and that are all involved in dendritic spine function and 
structure (Christiansen et al., 2017; Herring and Nicoll, 2016; Kerrisk et al., 2013; Minelli et al., 
2007; Youn et al., 2007). 
Possible sources of microglial defects in DS 
DS is caused by the triplication of a very long stretch of DNA, comprising 110-150 genes in humans 
(many of which are expressed by microglia (Mrak and Griffin, 2004). In the Dp(16) mouse model, 
113 genes are triplicated. Thus, it is very difficult to pinpoint the primary cause of the overall DS 
immunological dysfunction and the microglial defects we observed in this study. Nevertheless, at 
least 16 genes that are triplicated in both DS and Dp(16) mice are already known to play a direct 
role in the regulation of immune system activity (Li et al., 2007); Table 4). For example, the 
triplicated gene RUNX-1 encodes a transcription factor that plays a central role in microglia 
differentiation, proliferation and activation (Kierdorf and Prinz, 2013; Patel et al., 2011). In 
particular, RUNX-1 triplication could make the trisomic microglia highly sensitive to activating 
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stimuli such as IL-1, which we found increased in Dp(16) animals. Interestingly, the expression of 
IL-1 is constantly observed as increased also in DS individuals and can lead to microglia activation 
(Li et al., 1998; Liu et al., 2005; Wilcock and Griffin, 2013), which could generate a positive 
feedback loop in DS. Moreover, since microglial activation can indirectly lead (via IL-1) to an 
increased expression of the amyloid precursor protein (APP) gene (triplicated in DS and able to 
increase neuroinflammation per se), this would generate a second positive feedback loop that 
would further sustain microglia activation in the trisomic environment (Mrak and Griffin, 2004; 
Wilcock and Griffin, 2013). 
Microglia in individuals with DS 
Our results obtained from the analysis of postmortem brains of adult human subjects with DS 
suggest increased levels of hippocampal microglial activation, consistent with the chronic high 
level of inflammation reported in individuals with DS (Broers et al., 2014; Fructuoso et al., 2018; 
Gally et al., 2018; Sullivan et al., 2017). In particular, we found increased Iba1 expression and 
morphological alterations. These results were strikingly similar to the ones we observed in the 
Dp(16) mice. Only a limited number of studies have investigated microglia in individuals with DS, 
but they mostly focused on the effect of Alzheimer’s Disease (AD) on microglia, as virtually all 
individuals with DS develop symptoms of AD by the age of 40 (Dekker et al., 2017). Thus, in the 
few studies investigating microglia in individuals with DS, brains with very advanced AD were 
purposely chosen, and investigations focused on the effect of the amyloid Aβ burden. In these 
studies, microglia were often found in a senescent state (dystrophic and less responsive to stimuli) 
similar to what is described in AD (Streit et al., 2014; Xue and Streit, 2011). Conversely, of our 15 
brain samples of individuals with DS, only 3 presented diagnose of AD (no indication of the 
progression of the disease), and 3 presented only some anatomical signs of AD (low burden of Aβ 
or fibrillary tau). Notably, the presence or absence of AD or signs of AD did not influence the 
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morphological abnormalities we observed in our DS samples. Indeed, the microglia from the DS 
brains with AD or signs of AD showed the same level of impairment of the microglia from non-AD 
brains. This could be because the trisomy itself activates microglia, and a low burden of Aβ/ 
fibrillary tau or AD possibly not in a very advanced state cannot further change the morphology of 
those cells. On the other hand, the fact that we could not find any difference between the 
microglia of the 5 healthy controls and the 3 controls with some signs of AD would just favor the 
hypothesis that, unless AD is in a very late progression, microglia do not show signs of activation. 
Our study investigated microglia only at late postnatal ages. Nevertheless, some scant evidence of 
defective microglia exists for DS fetuses. Indeed, only a few studies out of the many performed on 
DS fetuses addressed microglia. These studies showed a decreased microglia cell density in the 
developing temporal cortex and an increase in the developing prefrontal cortex (Kanaumi et al., 
2013; Wierzba-Bobrowicz et al., 1999; Xue and Streit, 2011). Nevertheless, none of these studies 
addressed microglial morphology. Moreover, whether these changes in the density of microglia in 
DS fetuses could play a role in the paucity of neurons and the dendritic spine deficits characteristic 
of DS (Kanaumi et al., 2013) is still not known. 
Anti-inflammatory treatments to improve cognitive impairment in DS 
Our conclusions that the cognitive impairments in Dp(16) mice depended on the high 
inflammation levels in these animals were strengthened by the results in mice treated with an 
inhibitor of the JAK1/2 signaling cascade (ruxolitinib), an essential pathway for immunological 
activation. Treatment with ruxolitinib significantly rescued the behavioral phenotype in Dp(16) 
mice and the microglial branching phenotype. Nevertheless, ruxolitinib failed to rescue microglial 
cell/body size. Given its importance for immunological signaling, it is sensible to expect that there 
are mechanisms to compensate for a deficit of the JAK/STAT signaling (Seif et al., 2017). Therefore, 
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the only partial rescue of microglial morphology we observed upon ruxolitinib is not surprising. On 
the other hand, the fact that ruxolitinib treatment rescued the cognitive performances in Dp(16) 
animals (although seemingly to lower levels than APAP) may be because it is the physical 
interaction between the ramifications of the microglia and the dendritic spines themselves (rather 
than the activated state of microglia with increased body size) that is crucial for dendritic spine 
remodeling.  
Acetaminophen as a treatment for cognitive impairment in DS 
In this study, we showed that treatment with acetaminophen (APAP) fully rescued the 
morphological defects of trisomic microglia and concomitantly decreased the pro-inflammatory 
cytokines in the hippocampus of Dp(16) mice. Moreover, in our experiments, APAP treatment 
successfully rescued the spine density and mEPSCs, the levels of drebrin, and the cognitive 
performance of trisomic animals. APAP is a nonsteroidal anti-inflammatory drug (NSAID) that 
decreases the synthesis of prostaglandins (PGE) and has antipyretic and analgesic effects. 
Although APAP is considered not to have a solid anti-inflammatory effect (Jozwiak-Bebenista and 
Nowak, 2014), it strongly inhibits PGE production by microglial cells, already at low concentrations 
(Ajmone-Cat et al., 2010; Greco et al., 2003). In addition, APAP is active in the central nervous 
system (Flower and Vane, 1972; Jozwiak-Bebenista and Nowak, 2014), and although its effects on 
cognition in humans are not known, APAP can indeed change complex human behaviors such as 
social anxiety (Dewall et al., 2010; Fung and Alden, 2017), empathy (Mischkowski et al., 2016) and 
social well-being (Chibnall et al., 2005).  
Although APAP is well known for being a potential hepatotoxic drug in the case of overdose, it is 
extremely safe even at relatively high doses (up to 4 grams daily for adults). Indeed, even at high 
doses, it lacks the gastric side effects typical of classical NSAIDs (Ajmone-Cat et al., 2010). Thus, 
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APAP is a good candidate for drug repurposing for long-term treatments (Strittmatter, 2014). In 
addition, APAP is considered so safe that it is routinely prescribed as an anti-inflammatory 
treatment to pregnant women. Therefore, APAP could also be a good candidate as a drug 
treatment at early stages of development. Interestingly, APAP was able to rescue ASD-like 
behaviors including sociability in animal models of DS, suggesting that it could be an interesting 
treatment for neurodevelopmental disorders (Gould et al., 2012; Kim et al., 2018). Since DS is a 
neurodevelopmental disorder, the treatment of DS subjects during gestation could potentially 
lead to even more positive outcomes on their cognitive performance. Nevertheless, our study only 
focused on late postnatal development, and further studies during perinatal ages will be necessary 
to address whether an earlier treatment with APAP could be beneficial in DS. Moreover, recent 
studies on WT animals and humans has begun to raise some concerns about the safety of APAP 
during gestation and early postnatal stages because it can influence physiological brain 
development (Blecharz-Klin et al., 2015; Blecharz-Klin et al., 2018; Good, 2018; Philippot et al., 
2017; Schultz and Gould, 2016; Viberg et al., 2014). However, these detrimental effects on CNS 
development may be due to specific actions of APAP on WT embryos and may not apply to DS. 
Indeed, in our current study, APAP treatment had an opposite effect on the WT microglia, 
dendritic spines and mEPSCs in comparison to Dp(16) mice, and consistently decreased cognitive 
performance in WT mice. In line with our results, it was previously shown that the administration 
of APAP to WT rats caused a significant decrease in spatial memory, social behavior and 
exploratory behavior (Blecharz-Klin et al., 2018; Ishida et al., 2007). Moreover, it was recently 
shown that a single administration of APAP (100mg/kg) caused deficits in memory recognition and 
ERK phosphorylation in the hippocampus of mice (Milewski and Orr, 2018). Remarkably, 
Minocycline, a non-NSAID anti-inflammatory drug, administration causes a paradoxical increase in 
the alertness of microglial cells in a similar fashion we observed for APAP (Arnoux et al., 2014). 
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This could indicate the existence of a common mechanism of increased alertness in the presence 
of xenobiotics that is, at least in our case, genotype-dependent. The effect of APAP on WT animals 
may be due to unknown off-targets and may be independent of a direct effect on microglia. 
Accordingly, APAP had no effect on the levels of cytokines in WT animals. On the other hand, the 
correlation between overactive microglia, impaired spine density and function, and decreased 
cognition that we found in WT animals treated with APAP still suggests an active role of microglia 
at some level in the behavioral impairment. This active role of microglia in the defective cognition 
of APAP-treated WT animals could be indirectly caused by an off target effect of APAP treatment. 
For example, a high dose of APAP can be toxic to neurons, which in turn could activate microglia 
(Posadas et al., 2010). Thus, it is possible that the dose we used in our experiments (100 
mg/kg/day for 3 days) had a toxic effect on a WT organism (perhaps through specific toxicity to 
neurons), although the same dose had a positive effect in a trisomic environment. 
The different effects of APAP treatment on WT and trisomic animals call for some considerations 
on the current methods of validation of the efficacy of new pharmacological therapies (i.e., clinical 
trials). Indeed, according to the Food and Drug Administration (FDA), approximately 30% of new 
drugs are discontinued after phase I clinical trials 
(https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm), which involves an initial 
testing of the safety, side effects, best dose, and formulation method for the drug in healthy 
volunteers. Based on our observations with APAP, drug treatments could have completely 
different outcomes based on the presence or absence of morbidity. This could mean that 
potentially valuable drugs for the treatment of certain conditions are erroneously discarded during 
phase I clinical trials because of the appearance of adverse effects in healthy volunteers, which 





Our study proposes microglial dysregulation as one of the causes of the cognitive deficits in DS. In 
particular, we hypothesize that the hyperactive state of microglia, on a background of chronic 
neuroinflammation, causes a profound alteration in the functionality of neuronal circuits via 
hyper-activation of synaptic elimination, thus leading to cognitive deficits. Remarkably, the use of 
APAP (an over-the-counter anti-inflammatory drug) is able to fully recover the aforementioned 
deficits in Dp(16) mouse model of DS. Thus, our results open up to the possibility of repurposing 















MATERIALS AND METHODS 
All care of animals and experimental procedures were conducted in accordance with IIT licensing 
and were approved by the Italian Ministry of Health. All animals were housed in a climate-
controlled animal facility (22 ± 2°C) and maintained on a 12 h light/dark cycle with ad libitum 
access to food and water. The Dp(16)1Yey/+ animals were bought from The Jackson Laboratory 
(B6.129S7-Dp(16Lipi-Zbtb21)1Yey/J, catalog No 013530) and were used to create a colony by 
mating Dp(16) males with C57BL6/J females.  
Drug treatments. PLX3397 (Pexidartinib) was purchased from Selleckem (catalog No. S7818). The 
powder was dissolved in Dimethyl Sulfoxide (DMSO; Sigma-Aldrich, catalog No 276855) to 
generate an 83mg/mL (198.65 mM) solution. The solution was then added to pulverized mouse 
chow at a concentration of 445 mg/kg of chow and given to animals ad libitum from P15 to P22. 
The final dosage of around 4.7 mg total of drug/mouse over the 7 days of treatment was 
calculated on an average of 1.5 g of chow consumed by each mouse/day (Bachmanov et al., 2002). 
Acetaminophen (APAP) was purchased from Sigma-Aldrich (catalog No A7085). The powder was 
dissolved in DMSO to generate a 500mg/mL (3.3M) stock solution and subsequently diluted in 
saline (NaCl 0.9% w/v) to generate a 10mg/mL (66.15 mM) solution. This solution was injected 
intraperitoneally (IP) to animals with a dosage of 100mg/kg (10μL/g of solution for a total of 2% 
DMSO) daily from P20 to P22. Ruxolitinib was purchased from Selleckem (catalog No. S1378). The 
powder was dissolved in DMSO to generate a 61mg/mL (199.1mM) stock solution and 
subsequently diluted in saline (NaCl 0.9% w/v) to generate a 1.25mg/mL (4.08 mM) solution. This 
solution was injected subcutaneously to animals with a dosage of 50mg/kg (40μL/g of solution for 
a total of 2% DMSO) twice a day from P20 to P22. Due to the insolubility of the Ruxolitinib-DMSO 
solution in saline, a light sonication was applied until full solubility was obtained. The solution was 
kept in ice during sonication to avoid overheating. 
 
69 
All injected drugs were dissolved in the same vehicle (2% DMSO v/v in Saline). To decrease the 
number of utilized animals in agreement with ethic directions from the Italian Ministry of Health, 
all vehicle treated animals from all experiments were pulled together. PLX3397-treated animals 
were compared to the 2% DMSO treated animals as well (refer to the Statistical methods section 
for further information on how these data were analyzed). For every acetaminophen or 
ruxolitinib-treated litter, at least one animal of each strain was treated with vehicle (except for 3 
cases out of 19 total where the number of animals in a given litter did not allowed for such 
precaution and only 1 or no controls were assigned to the litter). 
Slice histology, immunostaining, image acquisition and analysis. P22 brains were fixed by 
transcardial perfusion with PBS 1X followed by PFA solution (4% w/v in PB). Then, brains were 
cryopreserved in sucrose (30% w/v) and sectioned coronally in 50 µm thick slices with a 
microtome-refrigerator (Micron HM 450 Sliding Microtome equipped with Freezing Unit Micron 
KS34, Thermo Scientific).  
For immunostaining, an antigen retrieval protocol was applied on free-floating slices. In brief, 
slices were incubated for 30 minutes in Sodium citrate buffer (10 mM Sodium citrate, 0.05% 
Tween 20, pH 6.0) at 90°C and subsequently let cool down to room temperature and washed in 
PBS1X. Slices were then permeabilized and blocked with PBS containing 0.3% Triton X-100 and 
10% NGS. Primary antibodies were incubated in PBS containing 0.3% Triton X-100 and 5% NGS 
overnight [rabbit anti-Iba1, 1:300 (WAKO, catalog No. 019-19741), rat anti-LAMP1, 1:300 (Santa 
Cruz Biotechnology, catalog No. sc-19992), rat anti-MHCII, 1:100 (Santa Cruz Biotechnology, 
catalog No. sc-59322)]. Immunostaining was detected using Alexa 488 (for Iba1) or Alexa 543 (for 
LAMP1 and MHCII) fluorescent secondary antibody (Invitrogen), 1:600, incubated in PBS 
containing 0.3% Triton X-100 and 5% NGS. Slices were counterstained with Hoechst (2,5 µg/µL; 
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Sigma). All slices were mounted in Vectashield Mounting Medium (Vector Laboratories, 
Burlingame, CA).  
For microglial cell count and morphology analysis, a stack of images spanning the whole thickness 
of the slice (1 µm thick z-stacks) from stained hippocampal slices were acquired using a confocal 
laser-scanning microscope (TCS SP5; Leica Microsystems, Milan, Italy) equipped with a 40x (NA 
1.25) immersion objective and projected on a 2D image. One randomly chosen slice per animal 
was acquired and cells from DG, CA1 and CA3 areas from the hippocampus were chosen in a 
balanced manner. For the somatosensory cortex cells from all layers were selected in a balanced 
manner. For cell count, the number of cells was divided by the total area of the acquired field to 
represent cell density. For the calculation of the cell-body area, the measurements were 
performed using the freehand selection tool in ImageJ. Sholl analysis was performed as previously 
described (Sipe et al., 2016). Briefly, cells were cropped and thresholded to generate a binary 
(black and white) image. The background was manually cleaned for each cell and the ImageJ 
plugin Sholl Analysis (Ferreira et al., 2014) was used to perform the analysis (starting radius: 4μm, 
ending radius: 70μm, radius step size: 2μm, radius span: 0μm). For skeleton analysis, the same 
binary image created for Sholl Analysis was used. The image was skeletonized using the ImageJ 
Plugin Skeletonize3D (Lee T.C., 1994) and was subsequently analyzed using the plugin 
AnalyzeSkeleton (Arganda-Carreras et al., 2010). 
For the analysis of MHCII/Iba1 staining co-localization area, a stack of images spanning the whole 
thickness of the slice (0.5 µm thick z-stacks) from stained hippocampal slices were acquired using a 
confocal laser-scanning microscope (TCS SP5; Leica Microsystems, Milan, Italy) equipped with a 
63x (NA 1. 5) immersion objective and projected on a 2D image. Each channel (Iba1 and MHCII) 
was thresholded to generate a binary (black and white) image using ImageJ. The background of 
Iba1 binary image only was manually cleaned to ensure that only one cell was present. 
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Subsequently, the two images were merged, converted to 32-bit and thresholded again to 
generate a binary image of only the pixels that came from both MHCII and Iba1 images. The area 
of the double positive pixels was calculated and divided by the area of the Iba1 positive pixels only 
for normalization. One randomly chosen slice per animal was acquired. 
Western Blotting. All hippocampus samples were lysed in RIPA buffer (150 mM NaCl, 50 mM 
HEPES, 0.5% NP40, 1% Sodiumdeoxycholate). After 30 minutes on ice, the lysates were clarified by 
centrifugation for 20 minutes at 16,000g. The protein samples were measured via Pierce BCA 
assay (Thermo-Fisher, Catalog No. 23225). For protein identification and relative quantification via 
Western blotting, a proper volume of sample containing an equal amount of proteins was diluted 
with 25% NuPAGE™ LDS Sample Buffer (4X; Thermo-Fisher, Catalog No. NP0007) and 5% 1,4-
Dithiothreitol (DTT; equivalent of 50mM, Sigma-Aldrich, Catalog No. DTT-RO Roche) and loaded 
onto NuPAGE™ 4-12% Bis-Tris Midi Protein gels (Thermo-Fisher, Catalog No. WG1402BOX). The 
proteins were then transferred onto nitrocellulose membrane (Sigma-Aldrich, catalog No. 
GE10600001) at 200mA overnight at 4◦C. The primary antibodies [rabbit anti-Iba1 1:1000 (WAKO, 
catalog No. 016-20001), rat anti-LAMP1, 1:500 (Santa Cruz Biotechnology, catalog No. sc-19992), 
mouse anti-Drebrin 1:600 (Enzo Lifesciences, catalog No. ADI-NBA-110-E), chicken anti-GAPDH 
1:2000 (Merck Millipore, catalog No AB2302) and rabbit anti-Actin 1:2500 (Sigma-Aldrich, catalog 
No A2066)] were then applied overnight in a blocking buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 
0.1% Tween 20, and 5% nonfat dry milk). The HRP-conjugated secondary antibodies [ Thermo-
Fisher, anti-mouse (catalog No 31430), anti-rabbit (catalog No 31460), anti-rat (catalog No 31470) 
or anti-chicken (catalog No PA1-28798)] were all used in a ratio of 1:2500. The signal was detected 
using the SuperSignal™ West Pico PLUS Chemiluminescent Substrate detection system (Thermo-
Fisher, catalog No 34578). Images were acquired by the Image Quant LAS 4000 mini image system 
(General-Electrics Healthcare) and protein quantification was performed by measuring the optical 
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density of the specific bands with the Image Quant TL software (General-Electrics Healthcare). 
Samples from all experimental groups were loaded on each experiment and normalized to the WT 
treated with vehicle. For statistical analysis, normalized data across independent experiments 
were used together. 
Cytokine assay. The mouse Inflammation Array C1 was purchased from Ray Biotech (catalog No 
AAM-INF-1). The hippocampal samples were lysed in RIPA buffer in the same way as for western-
blotting. The protein quantification was performed by Pierce BCA assay (Thermo-Fisher, Catalog 
No. 23225), following manufacturer’s instructions. The arrays were incubated with the 
hippocampal lysate over night at 4°C, then incubated with biotinylated secondary antibodies and 
HRP (both provided together with the arrays) following manufacturer’s instructions. The 
bioluminescence emitted by the arrays were acquired by the Image Quant LAS 4000 mini image 
system (General-Electrics Healthcare) and dot quantification was performed by measuring the 
optical density of each dot using the oval tool in ImageJ. The same area was used to quantify all 
the arrays. The data were analyzed following manufacturer’s instructions. In brief, the arrays were 
analyzed in pairs where one of the arrays was used as reference (array X below) and the other was 
expressed as fold change (array Y below). For each dot, the following formula was used: X(Ny) = 
X(y)*P1/P(y), where P1 is the mean signal for the positive control on the reference array (here 
called array X), P(y) is the mean signal for the positive control on the other array of the pair (here 
called array Y), X(y) is the raw quantification of a dot being analyzed and X(Ny) is the normalized 
quantification of the same dot. X(Ny) was then divided by the same dot’s signal on array X giving a 
fold change quantification for each single dot. 
Behavioral experiments. The behavioral experiments were performed between P20 and P22 on 
both male and female animals.  
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The Novel Object Recognition test (NOR) was performed as previously described(Deidda et al., 
2015). In brief, a gray acrylic arena (44 × 44 cm) was used. On the day before the NOR test, the 
mice were allowed to become habituated to the apparatus by freely exploring the open arena for 
15 min. During the acquisition sessions, three different objects different in shape, color, size and 
material were placed into the arena, and the mice were allowed to explore for 15 min (Fig. 25a). 
The object exploration and preference was evaluated during these sessions to rule out any 
eventual intrinsic bias (Fig. 25b-c). The testing occurred 24 h later in the same arena. In the test, 
one of the objects used in the acquisition session was replaced by a novel object, and the mice 
were allowed to explore freely for 15 min. The objects were counterbalanced between the 
sessions and were cleaned with 70% ethanol after each trial as well as the arena. The exploratory 
behavior toward an object was defined as direct contact with the object by the animal's mouth, 
nose or paws or as an instance when the animal approached the object so that its nose was within 
1 cm of the object. Any indirect or accidental contact with the objects was not included in the 
scoring. The time spent exploring each object, expressed as a percentage of the total exploration 
time, was measured for each trial. The discrimination index was calculated as the difference 
between the percentage of time spent investigating the novel object and that of time spent 
investigating the familiar objects: Discrimination Index = ((Novel Object Exploration Time/Total 




Figure 25. Covered distance, exploration time and object preference in the novel object 
recognition test. (a) Quantification of the total covered distance during the habituation phase of 
the novel object recognition test by animals treated with vehicle, PLX3397, APAP, or Ruxolitinib. 
No significant differences were found among the groups. Bar plots represent the average covered 
distance ± SEM. Numbers in parenthesis: analyzed animals. (b) Quantification of the total object 
exploration time in the acquisition phases of the novel object recognition test by animals treated 
with vehicle, PLX3397, APAP, or Ruxolitinib. No significant differences were found among the 
groups. Bar plots represent the average object exploration time ± SEM. Numbers in parenthesis: 
analyzed animals. (c) Quantification of the percentage of time spent exploring the three objects 
during the acquisition phase by animals treated with vehicle, PLX3397, APAP, or Ruxolitinib. No 
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significant biases were found among the groups. Bar plots represent the average percentage of 
exploration for each object ± SEM. Numbers in parenthesis: analyzed animals. 
 
The Object Location Test (OLT) was performed as previously described (Deidda et al., 2015). In 
brief, a gray acrylic arena (44 × 44 cm) was used. On the day before the NOR test, the mice were 
allowed to become habituated to the apparatus by freely exploring the open arena for 15 min (Fig. 
26a). The next day, the mice were exposed to two identical objects for 15 min during the 
acquisition phase. The object preference was evaluated during this session to rule out any 
eventual intrinsic bias (Fig. 26b-c). The testing occurred 24 h later in the same arena. During the 
trial session, one of the objects was moved to a novel location, and the mice were allowed to 
explore the objects for 15 min. The objects and the arena were cleaned with 70% ethanol after 
each trial. The time mice spent exploring each object was measured. The exploratory behavior 
toward an object was defined as direct contact with the object by the animal's mouth, nose or 
paws or as an instance when the animal approached the object so that its nose was within 1 cm of 
the object. Any indirect or accidental contact with the objects was not included in the scoring. The 
time spent exploring each object, expressed as a percentage of the total exploration time, was 
measured for each trial. The discrimination index was calculated as the percentage of time spent 
investigating the object in the new location minus the percentage of time spent investigating the 
object in the old location: Discrimination Index = ((New Object Location Exploration Time/Total 
Exploration Time) × 100) − ((Old Object Location Exploration Time/Total Exploration Time) × 100). 
The WT animals treated with APAP showed a small intrinsically preference for object 1 (on average 
animals explored 5.04% more object 1 than object 2 during acquisition). The bias did not affect the 
results on the testing day. The DI obtained from APAP treated WT animals in which the object in 
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the new location was object 1 as opposed to object 2 (3.43±SEM with N=5 vs. 7.73±SEM with 
N=7), was not significantly different.  
 
Figure 26. Covered distance, exploration time and object preference in the object location test. 
(a) Quantification of the total covered distance during the habituation phase of the object location 
test by animals treated with vehicle, PLX3397, APAP, or Ruxolitinib. No significant differences were 
found among groups. Bar plots represent the average covered distance ± SEM. Numbers in 
parenthesis: analyzed animals. (b) Quantification of the total object exploration time in the 
acquisition phases of the object location test by animals treated with vehicle, PLX3397, APAP, or 
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Ruxolitinib. No significant differences were found among groups. Bar plots represent the average 
object exploration time ± SEM. Numbers in parenthesis: analyzed animals. (c) Quantification of the 
percentage of time spent exploring the three objects during the acquisition phase by animals 
treated with vehicle, PLX3397, APAP, or Ruxolitinib. Bar plots represent the average percentage of 
exploration for each object ± SEM. Only WT animals treated with APAP showed a significant bias vs 
object 1 (** p<0.01; Two-Way ANOVA, FInteraction (1, 40) = 10.95, p=0.0022; Holm-Sidak post-hoc 
test). Numbers in parenthesis: analyzed animals. 
 
In all the behavioral tests, both male and female animals were used. No difference in performance 
based on the sex of the animals was observed. Different sets of animals were used for NOR and 
OLT. 
Golgi-Cox staining, image acquisition and analysis. The animals were perfused transcardially with 
0.9% saline. Whole brains were dissected and immersed in the Golgi-Cox solution (5% potassium 
dichromate, 5% mercuric chloride and 5% potassium chromate) for 35 days. Then, the brains were 
transferred to a 30% sucrose solution and stored in the dark at 4°C. 200 µm-thick coronal slices 
were cut at room temperature with a microtome (Microm HM 450 Sliding Microtome) and 
transferred onto 1% gelatin-coated slides to initiate the staining process in humidified chambers. 
Ammonium hydroxide was applied for 10 minutes. Next, the slices were incubated in an increasing 
grade of ethanol (50%, 75%, 95% and 100%), then in xylene for 30 minutes, and finally mounted in 
DPX-Mounting medium (Sigma-Aldrich, Catalog No 06522). A stack of 80-150 focal images (1 µm 
thick z-stacks) per cell (for a total of 5 cells per animal) were acquired from randomly chosen 
cortical slices at the level of the somatosensory cortex on a Neurolucida microscope equipped 
with the software Neurolucida (MicroBrightField) and a 100X objective (NA 1.3). On each image 
stack, the apical dendrite of a neuron was visually identified, and spines were counted on the 
whole visible length of 3 collateral dendrites for each image and divided by this length using the 
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Reconstruct software, which allows for the measurement of spine length and width for an 
unbiased classification of spine types (Risher et al., 2014). The densities of spines for each dendrite 
were averaged per each image stack. All the chemicals were purchased from Sigma-Aldrich, unless 
otherwise specified. 
In vitro electrophysiology. P22-P30 mice were anesthetized with isoflurane and transcardially 
perfused with ice-cold cutting solution containing: 200 mM sucrose, 4 mM MgCl2, 2.5 mM KCl, 
1.25 mM NaH2PO4, 0.5 mM CaCl2, 25 mM NaHCO3 and 25 mM D-glucose (~300 mOsm, pH 7.4, 
oxygenated with 95% O2 and 5% CO2). Brains were removed and immersed in cutting solution. 
270μm-thick coronal slices (cut with VT1000S Leica Microsystem vibratome) were allowed to 
recover for 1 hour at 35°C in a solution containing: 117 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 
3 mM MgCl2, 0.5 mM CaCl2, 25 mM NaHCO3 and 25 mM glucose (~310 mOsm, pH 7.4, oxygenated 
with 95% O2 and 5% CO2). Recordings were performed in visually-identified CA1 neurons of the 
hippocampus at room temperature in artificial cerebrospinal fluid (ACSF) composed of: 117 mM 
NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 25 mM NaHCO3 and 25 mM 
glucose (~310 mOsm, pH 7.4, oxygenated with 95% O2 and 5% CO2). Patch pipettes were made 
from thick-wall borosilicate glass capillaries (Sutter Instrument, catalog No B150-86-7.5). The 
pipettes (5-7 mΩ) were filled with intracellular solution containing: 130 mM K-gluconate, 10 mM 
HEPES, 7 mM KCl, 0.6 mM EGTA, 4 mM Mg2ATP, 0.3 Mm Na3GTP, 10 mM Phosphocreatine. The 
pH was adjusted to 7.3 with HCl. Whole-cell recordings from CA1 neurons were performed only 
when the series resistances were in the range of 10–25 mΩ. Three-minute recordings of mEPSCs 
were performed after a 10-minute bath application of 20 μM of Bicuculline methiodide (HelloBio, 
catalog No HB0893) and 1 μM Tetradotoxin (TTX; HelloBio, catalog No HB1035) to isolate 
excitatory events. Data, filtered at 0.1 Hz and 5 kHz and sampled at 10 kHz, were acquired by a 
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patch-clamp amplifier (Multiclamp 700B, Molecular Devices) and analyzed using MiniAnalysis 
(Synaptosoft). All the chemicals were purchased from Sigma-Aldrich, unless otherwise specified. 
Electron microscopy. Pre-embedding immuno-labeling experiments were performed as previously 
described (Hebert-Chatelain et al., 2014). Briefly, P22 brains were fixed by transcardial perfusion 
with PBS 1X followed by PFA and Glutaraldehyde mixed solution (4% PFA, 0,2% Glutaraldehyde 
w/v in PB). Next, 70μm thick coronal sections were cut using a vibratome (VT1000S Leica 
Microsystem). After a pre-incubation in blocking solution (10% BSA, 0.1% sodium azide and 0.02% 
saponin in Tris-buffered saline (TBS), the sections were incubated with rabbit anti-Iba1, 1:300 
(WAKO, catalog No. 019-19741) in blocking solution with 0.004% saponin overnight at 4°C. After 
several washes with 1% BSA in TBS, the sections were processed using the mouse specific 
HRP/DAB (ABC) Detection IHC Kit (Abcam, catalog No ab64259). In brief, the sections were 
incubated for 2 hours with a goat anti-rabbit biotinylated secondary antibody, then with avidin-
biotin complex for 2 hours, and finally incubated in 0.05% diaminobenzidine (DAB) and 0.01% 
hydrogen peroxide mixed solution. After 10 minutes fixation with 1% glutaraldehyde solution, the 
sections were post-fixed in Osmium tetroxide 1% for 20 minutes, and stained 2h in aqueous 0.5% 
uranyl acetate solution. Then the samples were washed several times in distilled water, 
dehydrated in a graded ethanol series (50%, 75%, 95% and 100%) and then embedded in EPON 
resin. 70nm-thick sections of the CA1 hippocampal region were collected with a Leica EMU C6 
ultra-microtome. Transmission electron microscopy (TEM) micrographs were collected with Jeol 
JEM 1011 (Jeol, Tokyo, Japan) electron microscope (Electron Microscopy Facility – Fondazione 
Istituto Italiano di Tecnologia, Genoa, Italy), operating at an acceleration voltage of 100 kV, and 
recorded with a 11 Mp fiber optical charge-coupled device (CCD) camera (Gatan Orius SC-1000, 
Gatan, USA) at 10,000x. The images were then quantified as previously described (Sipe et al., 
2016). The post-synaptic elements were identified primarily by the presence of electron-dense 
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accumulations (postsynaptic densities) when contacting pre-synaptic elements, but also by the 
absence of mitochondria and rounded morphologies. The pre-synaptic elements were primarily 
identified by the presence of ~40nm-diameter synaptic vesicles, but also by synaptic contacts with 
dendritic shafts and post-synaptic elements and the often-present mitochondria. The interactions 
were calculated by dividing the number of contacts (per Iba1-labelled process) by the area of the 
microglial processes (expressed in μm2) and averaging across processes (40-55 per animal). 
Human Samples.  
Western Blotting. Samples used for Western-Blot are the same used in Deidda et al. 2015 (Deidda 
et al., 2015). None of these samples All hippocampus samples were lysed in RIPA buffer (150 mM 
NaCl, 50 mM HEPES, 0.5% NP40, 1% Sodiumdeoxycholate). After 30 minutes on ice, the lysates 
were clarified by centrifugation for 20 minutes at 16,000g. The proteins were measured via Pierce 
BCA assay (Thermo-Fisher, Catalog No. 23225). For protein identification and relative 
quantification via Western blotting, a proper volume of sample containing an equal amount of 
proteins was diluted with 25% NuPAGE™ LDS Sample Buffer (4X; Thermo-Fisher, Catalog No. 
NP0007) and 5% 1,4-Dithiothreitol (DTT; equivalent of 50mM, Sigma-Aldrich, Catalog No. DTT-RO 
Roche), and loaded onto NuPAGE™ 4-12% Bis-Tris Midi Protein gels (Thermo-Fisher, Catalog No. 
WG1402BOX). The proteins were then transferred onto nitrocellulose membrane that was 
previously incubated with Transfer Buffer for 15 minutes (Sigma-Aldrich, catalog No. GE10600001) 
at 200mA overnight at 4◦C. The primary antibody [rabbit anti-Iba1 1:1000 (WAKO, catalog No. 016-
20001)] was then applied overnight in a blocking buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% 
Tween 20, and 5% nonfat dry milk). The HRP-conjugated secondary antibodies [Thermo-Fisher, 
anti-rabbit (catalog No 31460)] was used in a ratio of 1:2500. The signal was detected using the 
SuperSignal™ West Pico PLUS Chemiluminescent Substrate detection system (Thermo-Fisher, 
catalog No 34578). Images were acquired by the Image Quant LAS 4000 mini image system 
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(General-Electrics Healthcare) and protein quantification was performed by measuring the optical 
density of the specific bands with the Image Quant TL software (General-Electrics Healthcare). The 
samples were loaded in three independent gels and averaged across experiments. 
Slice histology, immunostaining, image acquisition and analysis. Human samples used for 
immunohistochemistry (Supplementary Table 3) were obtained from two different sources: 
Biobank HCB – IDIBAPS (Barcelona, Spain) and NeuroBioBank (USA). Hippocampi were fixed (24h, 
PFA 4% (w/v) in PBS 1X), cryoprotected (sucrose 30%, w/v) and stored at -80°C. Samples from HCB 
– IDIBAPS were taken from 4 controls (40-86 years-old, postmortem interval (PMI) 7-16h) and 4 
individuals with DS (36-67 years-old, PMI 9-22h). Samples from the NeuroBioBank were taken 
from 8 controls (36-56 years-old, PMI 8-21h) and 6 individuals with DS (25-57 years-old, PMI 3-
22h). Tissue blocks were cut using a vibratome (VT1000S Leica Microsystem vibratome) into 8-
10μm thick (samples from HCB-IDIBAPS) or 25 μm thick (samples from NeuroBioBank) sections. 
Sections were then incubated with citrate buffer (0.01M, pH 6.0) for 1 minute at 100 ºC. Next, 
sections were treated for 1 h with 5% normal donkey serum (NDS, Jackson Immuno-Research 
Laboratories, catalog No 017-000-121) in PBS 1X with 0.2% Triton- X100 and incubated overnight 
at room temperature with mouse monoclonal IgG anti-Iba1 1:500 (Chemicon, Catalog No 
MABN92). After washing, sections were incubated with secondary antibody (Alexa 488 donkey 
anti-mouse IgG 1:200 (Invitrogen, Catalog No. A-21202). After further washing, sections were then 
mounted using Dako fluorescent medium (Dako North America, Catalog No. S3023). For microglial 
morphology analysis, a stack of images spanning the whole thickness of the slice (1.15 µm thick z-
stacks) from stained hippocampal slices were acquired using a confocal laser-scanning microscope 
(TSC-SPE; Leica Microsystems) equipped with a 40x (NA 1.25) immersion objective and projected 
on a 2D image. For calculation of the cell-body area, the measurements were performed using the 
freehand selection tool in ImageJ. Sholl analysis was performed as previously described(Sipe et al., 
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2016). Briefly, cells were cropped and thresholded to generate a binary (black and white) image. 
The background was manually cleaned for each cell and the ImageJ plugin ShollAnalysis (Ferreira 
et al., 2014) was used to perform the analysis (starting radius: 4μm, ending radius: 70μm, radius 
step size: 2μm, radius span: 0μm). For skeleton analysis, the same binary image created for Sholl 
Analysis was used. The image was skeletonized using the ImageJ Plugin Skeletonize3D(Lee T.C., 
1994) and was subsequently analyzed using the plugin AnalyzeSkeleton (Arganda-Carreras et al., 
2010). 
Mass-Spectrometry Based Proteomics.  
Sample preparation. Samples of hippocampi Dp(16) and WT littermates were lysed by FASP 
protocol(Wisniewski et al., 2009) using the FASP Protein Digestion Kit (Expedeon Inc, Cat. No. 
44250). Briefly, the samples were mixed with 0.3ml of 8M Urea in 0.1M Tris/HCl pH 8.5 (UA 
solution), loaded into the filtration devices, alkylated in 0.1ml of 50mM iodoacetamide in UA 
solution for 1 h in darkness at RT. The samples were digested using sequentially 1 µg of LysC and 
1µg of Trypsin in 50 mM NaHCO3 solution at 37°C overnight. The obtained peptides were 
collected by centrifugation of the filter units for 10 min and the filter devices were rinsed with two 
40 µl washes 50mM NaHCO3 and 50µl 0.5M NaCl to eliminate the hydrophobic interactions.  
NanoLC and mass spectrometer setup. The prepared samples were loaded directly into the 
separation column and the peptides were eluted with a non-linear gradient of 5-65 % solution B 
(80% CAN and 20% H2O, 5% DMSO, 0.1% FA) in 180min at a flow rate of 250nl/min. The peptide 
separations were carried out at 55°C by a 75-μm ID×50cm 2μm, 100 Å C18 column mounted in the 
thermostatic column compartment of the machine. Eluting peptides were electrosprayed and 
analyzed by tandem mass spectrometry on an Orbitrap Fusion Tribrid (Thermo Fischer Scientific) 
operating in positive ionization mode. The precursors were ionized using an EASY-spray source 
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held at +2.2kV and the inlet capillary temperature was held at 300°C. Single MS survey scans were 
performed in the Orbitrap, recording a mass window between 375 –1500 m/z with an AGC target 
of 250,000, at maximum injection time of 50ms, and a resolution of 120,000 at 200 m/z. 
Monoisotopic precursor selection was enabled for peptide isotopic distributions, precursors of 
z=2-5 were selected for 2 seconds of cycle time, and dynamic exclusion was set to 45 seconds with 
a ±10 ppm window set around the precursor. HCD (High-energy Collisional Dissociation) was 
performed with a target value of 10,000 ions in the linear ion trap, a maximal ion injection time of 
45ms, normalized collision energy of 30%, a Q-value of 0.25 and the possibility to inject ions for all 
available parallelizable time was enabled. The mass spectrometry proteomic data were deposited 
to the ProteomeXchange Consortium via the PRIDE (Vizcaino et al., 2016) partner repository with 
the dataset identifier PXD000000.  
Proteomic data analysis. The raw data were processed with MaxQuant software(Cox and Mann, 
2008). The database used by the software was the Mouse human database (release 2016_02). For 
the search trypsin allowing for cleavage N‐terminal to proline was chosen as enzyme specificity. A 
contaminants database by the Andromeda search engine (Cox et al., 2011), with cysteine 
carbamidomethylation as fixed modification and acetylation protein N-terminal methionine 
oxidation and deamidation (N, Q) as variable modifications, were selected. For the identification of 
proteins, a false discovery rate (FDR) of 0.01 was requested. For peptide identification, peptides 
and peptide-spectrum match (PSM) and a minimum length of 6 amino acids were requested. 
Quantification in MaxQuant was performed using the built-in label-free quantification algorithm 
(Luber et al., 2010), enabling the “Match Between Runs” (Nagaraj et al., 2012). All proteins and 
peptides matching to the reversed database were filtered out. Label‐free protein quantitation 
(LFQ) was performed with a minimum ratio count of 1 (Cox et al., 2014). 
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Proteomic bioinformatic analysis. All bioinformatics analyses were performed with the Perseus 
software of the MaxQuant computational platform (Tyanova et al., 2016). Protein groups were 
filtered to require 100% valid values in at least one experimental group. The label-free intensities 
were expressed as base log2 and empty values were imputed with random numbers from a 
normal distribution for each column, to best simulate low abundance values close to the noise 
level. For each sample, a Student’s t-test with permutation-based FDR statistics was run. 250 
permutations were performed, with an s0 of 0.1 and required an FDR of 0.05. 
Targeted Proteomics. Targeted Peptides for drebrin protein were selected based on the data-
dependent analysis (DDA), experimental results and on the theoretical scores obtained by the 
Picky software (Zauber et al., 2018). Peptide samples were prepared using the same FASP protocol 
used for the discovery study and analyzed with an Orbitrap Fusion Tribrid mass spectrometer 
(Thermo Scientific) coupled to a Thermo/Dionex Ultimate 3000 Rapid Separation UPLC system and 
EasySpray nano source. Samples were separated on an EasySpray PepMap RSLC, C18, 2 μm 
particle, 75 μm x 50 cm column at a 250 nl/min flow rate. Solvent A was water and solvent B was a 
solution of acetonitrile, water and DMSO (80/20 at 5%, final v/v), each containing 0.1% (v/v) 
formic acid. After loading at 2% B for 5 min, peptides were separated using a 100-min gradient 
from 7-30% B and a 20-min gradient from 30-50% B, 5-min at 80% B, followed by a 20 min re-
equilibration at 2% B. Peptides were analyzed using the targeted MS2 mode of the Xcalibur 
software in which the doubly or triply charged precursor ion corresponding to each peptide was 
isolated in the quadrupole, fragmented by HCD, and full m/z 300-1200 scans of fragment ions at 
30,000 resolution collected in the Orbitrap. Targeted MS2 parameters included an isolation width 
of 1.8 m/z for each precursor of interest, collision energy of 28%, AGC target of 5 x 10e4, 
maximum ion injection time of 64 ms, spray voltage of 2200 V, and ion transfer temperature of 
300°C. A number of 10 precursors were targeted in each run and no scheduling was used. We used 
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the software package Skyline (MacLean et al., 2010) to generate precursor isolation lists for all 
peptides of interest and export them into the Orbitrap. Skyline was used to analyze targeted 
MS/MS data. Chromatographic and spectral data from RAW files were loaded into Skyline and 
manually analyzed to identify fragment ion peaks corresponding to each peptide. RAW files were 
also processed using MaxQuant software in order to match MS/MS spectra to the drebrin 
proteotype sequence peptide. Peak areas for all selected precursors and transitions in Skyline 
were combined for quantitation. For transitions refinement, we checked if all transitions were of 
good quality and reproducible over the samples. If certain transitions were of low quality (low 
intensity, high CV (%)) or irreproducible over runs, we removed them from the analysis. 
Statistical Analysis. For statistical analysis, the Graph Pad Prism 7 software (GraphPad Software, 
USA) was used. The statistical analysis was performed by Student’s t test (comparisons between 
two-groups), one-way analysis of variance (ANOVA) followed by Holm-Sidak post-hoc 
(comparisons among three or more groups) or two-way analysis of variance (ANOVA) followed by 
Holm-Sidak post hoc comparison (comparisons among more four or more groups with two 
different variables (i.e. Strain and Treatment). For heteroskedastic datasets and/or for datasets of 
non-normal distribution, Mann-Whitney test comparison (comparisons between two-groups) or 
Kruskal-Wallis test followed by Dunn’s post-hoc test (for comparison between three or more 
groups) were used. The Kolmogorov-Smirnov test was used to compare cumulative distributions. 
For datasets in Fig. 8e, 9d and 24d, independent One-Sample t-test against 0 for each cytokine was 
used. The outliers were excluded only from the final pool of data by a Grubb’s test iteratively until 
no outliers were found. In all cases, where the datasets from vehicle-treated animals were reused 
for comparison in different graphs, the statistical significance depicted in the graphs derives from 
one single two-way ANOVA including all groups across all figures. The T or F statistics reported in 
the figure legends derive from statistical tests including only the groups shown in each individual 
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graph. The statistics from experiments where we could not detect statistically significant 







































AD – Alzheimer’s Disease 
APAP – Acetaminophen  
APP – Amyloid Precursor Protein 
BBB – Blood Brain Barrier 
BDNF – Brain-Derived Neurotrophic Factor 
CNS – Central nervous System  
DS – Down Syndrome 
ERK – Extracellular Signal-Regulated Kinase  
HSA21 – Human Chromosome 21 
IFN – Interferon  
IL – Interleukin  
LPS – Lipopolysaccharide  
LTD – Long-Term Depression 
LTP – Long-Term Potentiation 
MCP – Monocyte Chemoattractant Protein-1  
MIP – Macrophage Inflammatory Protein 
MMU16 – Murine Chromosome 16 
NOR – Novel Object Recognition 
NSAID – Non-Steroidal Anti Inflammatory 
Drugs 
OLT – Object Location Test 
P – Postnatal Day 
PET – Positron-Emission Tomography 
PGE – Prostaglandin  
Poly I:C – Polyinosinic:polycytidylic Acid  
Redox – Reduction/Oxidation 
RTT – Rett Syndrome 
SVZ – Sub Ventricular Zone 
TNF – Tumor Necrosis Factor 
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